



STIC Search Report

Biotech-Chem Library

STIC Database Tracking Number: 188664

TO: Andrew D Kosar
Location: rem/3C04/3C18
Art Unit: 1654

Case Serial Number: 10/632366

From: P. Sheppard
Location: Remsen Building
Phone: (571) 272-2529

sheppard@uspto.gov

Search Notes

From: ANDREW KOSAR [andrew.kosar@uspto.gov]
Sent: Thursday, May 04, 2006 11:18 AM
To: STIC-Biotech/ChemLib
Subject: Database Search Request, Serial Number: 10632366

Requester:
ANDREW KOSAR (P/1654)

Art Unit:
GROUP ART UNIT 1654

Employee Number:
80341

Office Location:
REM 03C04

Phone Number:
(571) 272-0913

Mailbox Number:
REM 3c18

Case serial number:
10632366

Class / Subclass(es):

Earliest Priority Filing Date:

Format preferred for results:
Paper

Search Topic Information:
1) Please search SEQ ID NO:1

2) Please search preptin administered to a subject for increasing or maintaining beta-cell mass and/or beta-cell count.

3) please saerch SEQ ID NOs:1, 2 and 3 in the method (#2).

Special Instructions and Other Comments:

SEQ ID NO:1 is asserted to be human preptin. #2, rat and #3 mouse

Searcher: _____
Searcher Phone: _____
Date Searcher Picked up: _____
Date completed: _____
Searcher Prep Time: _____
Online Time: _____

Type of Search
NA# _____ AA# _____
S/L: _____ Oligomer: _____
Encode/Transl: _____
Structure #: _____ Text: _____
Inventor: _____ Litigation: _____

Vendors and cost where applicable
STN: _____
DIALOG: _____
QUESTEL/ORBIT: _____
LEXIS/NEXIS: _____
SEQUENCE SYSTEM: _____
WWW/Internet: _____
Other (Specify): _____

=> d his ful

(FILE 'HOME' ENTERED AT 10:45:36 ON 20 MAY 2006)

FILE 'REGISTRY' ENTERED AT 10:50:59 ON 20 MAY 2006

L1 76 SEA ABB=ON PLU=ON DVSTPPPTVLPDNFPYRPGKFFQYDTWKQSTQRL|DVSTSQAVLPDDFPYRPGKFFQYDTWRQSAGRL/S
LPDDFPYRPGKFFKFDTWRQSAGRL|DVSTSQAVLPDDFPYRPGKFFQYDTWRQSAGRL/S
QSP
E PREPTIN
L2 6 SEA ABB=ON PLU=ON PREPTIN/BI

FILE 'HCAPLUS' ENTERED AT 10:57:27 ON 20 MAY 2006

L3 64 SEA ABB=ON PLU=ON L1
L4 4 SEA ABB=ON PLU=ON L2 OR ?PREPTIN?
L5 4 SEA ABB=ON PLU=ON L3 AND L4
D STAT QUE
D IBIB ABS HITSTR L5 1-4
L6 133626 SEA ABB=ON PLU=ON ("BETA CELL PANCREATIC ISLET OF LANGERHANS"
/CV OR "PANCREATIC ISLET OF LANGERHANS (L) B-CELL"/CV) OR
BETA(W) CELL OR ?PANCREA? OR ISLET OR LANGERHAN?
L7 11 SEA ABB=ON PLU=ON L3 AND L6
L8 8 SEA ABB=ON PLU=ON L7 NOT L5
D STAT QUE L8
D IBIB ABS HITSTR L8 1-8
L9 1400588 SEA ABB=ON PLU=ON CELL(L) (FUNCT? OR IMPROV? OR PROLIFER? OR
INCREAS? OR REGULAT? OR GROWTH OR MAINT?)
L10 18 SEA ABB=ON PLU=ON (L9 AND L3) NOT (L5 OR L8)
E PREVENTIVE/RL
L11 21 SEA ABB=ON PLU=ON L3 (L) (?INSUL? OR ?DIABET? OR ?THERAP? OR
?PREVENT?)
L12 25 SEA ABB=ON PLU=ON (L10 OR L11) NOT (L5 OR L8)
D STAT QUE L12
D IBIB ABS HITSTR L12 1-25
SELECT HIT RN L8 1-8
SELECT HIT RN L12 1-25

FILE 'REGISTRY' ENTERED AT 11:06:08 ON 20 MAY 2006

L13 28 SEA ABB=ON PLU=ON (481287-00-7/BI OR 309257-18-9/BI OR
537723-29-8/BI OR 628822-82-2/BI OR 680884-69-9/BI OR 742221-41
-6/BI OR 853830-43-0/BI OR 93052-02-9/BI OR 94046-85-2/BI OR
96162-27-5/BI OR 93052-03-0/BI OR 253578-19-7/BI OR 253578-20-0
/BI OR 340836-88-6/BI OR 454747-09-2/BI OR 481286-95-7/BI OR
500742-70-1/BI OR 516534-81-9/BI OR 632394-04-8/BI OR 643773-30
-2/BI OR 671823-44-2/BI OR 746279-18-5/BI OR 746327-21-9/BI OR
746327-26-4/BI OR 864396-45-2/BI OR 869138-89-6/BI OR 871755-52
-1/BI OR 93927-44-7/BI)
L14 28 SEA ABB=ON PLU=ON L13 AND L1
D IDE CAN L2 1-6
D STAT QUE L14
D .SEQ L14 1-28

FILE HOME

FILE REGISTRY

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 19 MAY 2006 HIGHEST RN 885029-44-7

DICTIONARY FILE UPDATES: 19 MAY 2006 HIGHEST RN 885029-44-7

THIS PAGE BLANK (USPTO)

Kosar 10632366 - - History

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

```
*****  
*  
* The CA roles and document type information have been removed from *  
* the IDE default display format and the ED field has been added, *  
* effective March 20, 2005. A new display format, IDERL, is now *  
* available and contains the CA role and document type information. *  
*  
*****
```

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

FILE HCPLUS

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 20 May 2006 VOL 144 ISS 22
FILE LAST UPDATED: 19 May 2006 (20060519/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=>

THIS PAGE BLANK (USPTO)

Kosar 10632366

=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 10:57:27 ON 20 MAY 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 20 May 2006 VOL 144 ISS 22
FILE LAST UPDATED: 19 May 2006 (20060519/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=>
=>

=> d stat que
L1 76 SEA FILE=REGISTRY ABB=ON PLU=ON DVSTPPPTVLPDNFPRYPVGKFFQYDTWKQ
 STQRL|DVSTSQAVLPDDFPRYPVGKFFKFDTWRQSAGRL|DVSTSQAVLPDDFPRYPVGKFF
 QYDTWRQSAGRL/SQSP
L2 6 SEA FILE=REGISTRY ABB=ON PLU=ON PREPTIN/BI
L3 64 SEA FILE=HCAPLUS ABB=ON PLU=ON L1
L4 4 SEA FILE=HCAPLUS ABB=ON PLU=ON L2 OR ?PREPTIN?
L5 4 SEA FILE=HCAPLUS ABB=ON PLU=ON L3 AND L4

=>
=>

=> d ibib abs hitstr 15 1-4

L5 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004:120742 HCAPLUS
 DOCUMENT NUMBER: 140:157935
 TITLE: Preventive and therapeutic uses of compounds with
 preptin function
 INVENTOR(S): Cooper, Garth James Smith; Buchanan, Christine Maree;
 James, Gabriel Christopher
 PATENT ASSIGNEE(S): Protemix Corporation Limited, N. Z.
 SOURCE: PCT Int. Appl., 63 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004012761	A1	20040212	WO 2003-NZ171	20030801
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004142393	A1	20040722	US 2003-632366	20030731
CA 2494308	AA	20040212	CA 2003-2494308	20030801
AU 2003258895	A1	20040223	AU 2003-258895	20030801
EP 1534321	A1	20050601	EP 2003-766791	20030801
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006500341	T2	20060105	JP 2004-525887	20030801
PRIORITY APPLN. INFO.:			NZ 2002-520536	A 20020801
			US 2002-400445P	P 20020801
			WO 2003-NZ171	W 20030801

AB The invention features methods for treating various diseases, disorders and/or conditions, including injuries and wounds, as well as diseases, disorders and/or conditions for example that relate to or are characterized, in whole or in part, by decreased -cell mass, decreased -cell number, and/or decreased -cell function, in a subjects including humans and non-human animals. The methods include administering to a subject an effective amount of one or more compds. including preptins, preptin analogs, preptin agonists, salts thereof, and derivs. thereof.

IT 315197-69-4 315197-73-0 315197-75-2
 315197-75-2D, Preptin, analogs and derivs.
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (preventive and therapeutic uses of compds. with preptin function)

RN 315197-69-4 HCAPLUS

CN L-Leucine, L- α -aspartyl-L-valyl-L-seryl-L-threonyl-L-prolyl-L-prolyl-L-threonyl-L-valyl-L-leucyl-L-prolyl-L- α -aspartyl-L-asparaginyl-L-phenylalanyl-L-prolyl-L-arginyl-L-tyrosyl-L-prolyl-L-valylglycyl-L-lysyl-L-phenylalanyl-L-phenylalanyl-L-glutaminyl-L-tyrosyl-L- α -aspartyl-L-threonyl-L-tryptophyl-L-lysyl-L-glutaminyl-L-seryl-L-threonyl-L-glutaminyl-L-arginyl- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 315197-73-0 HCAPLUS

CN L-Leucine, L- α -aspartyl-L-valyl-L-seryl-L-threonyl-L-seryl-L-glutaminyl-L-alanyl-L-valyl-L-leucyl-L-prolyl-L- α -aspartyl-L- α -aspartyl-L-phenylalanyl-L-prolyl-L-arginyl-L-tyrosyl-L-prolyl-L-valylglycyl-L-lysyl-L-phenylalanyl-L-phenylalanyl-L-lysyl-L-phenylalanyl-L- α -aspartyl-L-threonyl-L-tryptophyl-L-arginyl-L-glutaminyl-L-seryl-L-alanylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 315197-75-2 HCAPLUS

CN L-Leucine, L- α -aspartyl-L-valyl-L-seryl-L-threonyl-L-seryl-L-glutaminyl-L-alanyl-L-valyl-L-leucyl-L-prolyl-L- α -aspartyl-L- α -aspartyl-L-phenylalanyl-L-prolyl-L-arginyl-L-tyrosyl-L-prolyl-L-valylglycyl-L-lysyl-L-phenylalanyl-L-phenylalanyl-L-glutaminyl-L-tyrosyl-L- α -aspartyl-L-threonyl-L-tryptophyl-L-arginyl-L-glutaminyl-L-seryl-L-alanylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 315197-75-2 HCAPLUS

CN L-Leucine, L- α -aspartyl-L-valyl-L-seryl-L-threonyl-L-seryl-L-glutaminyl-L-alanyl-L-valyl-L-leucyl-L-prolyl-L- α -aspartyl-L- α -aspartyl-L-phenylalanyl-L-prolyl-L-arginyl-L-tyrosyl-L-prolyl-L-valylglycyl-L-lysyl-L-phenylalanyl-L-phenylalanyl-L-glutaminyl-L-tyrosyl-L- α -aspartyl-L-threonyl-L-tryptophyl-L-arginyl-L-glutaminyl-L-seryl-L-alanylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L5 ANSWER 2 OF 4 HCPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004:120741 HCPLUS
 DOCUMENT NUMBER: 140:157934
 TITLE: *Preptin* analogs and methods for bone therapeutic use thereof
 INVENTOR(S): Cornish, Jillian; Reid, Ian Reginald; Cooper, Garth James Smith; Buchanan, Christina Maree
 PATENT ASSIGNEE(S): Auckland Uniservices Limited, N. Z.
 SOURCE: PCT Int. Appl., 29 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004012760	A1	20040212	WO 2003-NZ168	20030731
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2494305	AA	20040212	CA 2003-2494305	20030731
AU 2003281842	A1	20040223	AU 2003-281842	20030731
PRIORITY APPLN. INFO.:			US 2002-400443P	P 20020801
			WO 2003-NZ168	W 20030731

AB This invention features a method for treating a bone condition in a patient, e.g., a mammal, a human, a horse, a dog, or a cat. The method includes administering an effective amount of *preptin*, *preptin* analog, or a *preptin* agonist to the patient.

IT 315197-69-4 315197-73-0 315197-75-2

315197-75-2D, *Preptin*, analogs and agonists

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(*preptin* analogs and methods for bone therapeutic use thereof)

RN 315197-69-4 HCPLUS

CN L-Leucine, L- α -aspartyl-L-valyl-L-seryl-L-threonyl-L-prolyl-L-prolyl-L-threonyl-L-valyl-L-leucyl-L-prolyl-L- α -aspartyl-L-asparaginyl-L-phenylalanyl-L-prolyl-L-arginyl-L-tyrosyl-L-prolyl-L-valylglycyl-L-lysyl-L-phenylalanyl-L-phenylalanyl-L-glutaminyl-L-tyrosyl-L- α -aspartyl-L-threonyl-L-tryptophyl-L-lysyl-L-glutaminyl-L-seryl-L-threonyl-L-glutaminyl-L-arginyl- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 315197-73-0 HCPLUS

CN L-Leucine, L- α -aspartyl-L-valyl-L-seryl-L-threonyl-L-seryl-L-glutaminyl-L-alanyl-L-valyl-L-leucyl-L-prolyl-L- α -aspartyl-L- α -aspartyl-L-phenylalanyl-L-prolyl-L-arginyl-L-tyrosyl-L-prolyl-L-valylglycyl-L-lysyl-L-phenylalanyl-L-phenylalanyl-L- α -aspartyl-L-threonyl-L-tryptophyl-L-arginyl-L-glutaminyl-L-seryl-L-alanylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 315197-75-2 HCPLUS
CN L-Leucine, L- α -aspartyl-L-valyl-L-seryl-L-threonyl-L-seryl-L-glutaminyl-L-alanyl-L-valyl-L-leucyl-L-prolyl-L- α -aspartyl-L-phenylalanyl-L-prolyl-L-arginyl-L-tyrosyl-L-prolyl-L-valylglycyl-L-lysyl-L-phenylalanyl-L-phenylalanyl-L-glutaminyl-L-tyrosyl-L- α -aspartyl-L-threonyl-L-tryptophyl-L-arginyl-L-glutaminyl-L-seryl-L-alanylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 315197-75-2 HCPLUS
CN L-Leucine, L- α -aspartyl-L-valyl-L-seryl-L-threonyl-L-seryl-L-glutaminyl-L-alanyl-L-valyl-L-leucyl-L-prolyl-L- α -aspartyl-L-phenylalanyl-L-prolyl-L-arginyl-L-tyrosyl-L-prolyl-L-valylglycyl-L-lysyl-L-phenylalanyl-L-phenylalanyl-L-glutaminyl-L-tyrosyl-L- α -aspartyl-L-threonyl-L-tryptophyl-L-arginyl-L-glutaminyl-L-seryl-L-alanylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L5 ANSWER 3 OF 4 HCPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2001:925240 HCPLUS
 DOCUMENT NUMBER: 136:145438
 TITLE: **Preptin** derived from proinsulin-like growth factor II (proIGF-II) is secreted from pancreatic islet β -cells and enhances insulin secretion

AUTHOR(S): Buchanan, Christina M.; Phillips, Anthony R. J.; Cooper, Garth J. S.

CORPORATE SOURCE: School of Biological Sciences, Department of Medicine, School of Medicine, University of Auckland, Auckland, N. Z.

SOURCE: Biochemical Journal (2001), 360(2), 431-439
 CODEN: BIJOAK; ISSN: 0264-6021

PUBLISHER: Portland Press Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Pancreatic islet β -cells secrete the hormones insulin, amylin and pancreastatin. To search for further β -cell hormones, the authors purified peptides from secretory granules isolated from cultured murine BTC6-F7 β -cells. The authors identified a 34-amino-acid peptide (3948 Da), corresponding to Asp69-Leu102 of the proinsulin-like growth factor II E-peptide, which the authors have termed "**preptin**".
Preptin, is present in islet β -cells and undergoes glucose-mediated co-secretion with insulin. Synthetic **preptin** increases insulin secretion from glucose-stimulated BTC6-F7 cells in a concentration-dependent and saturable manner. **Preptin** infusion into the isolated, perfused rat pancreas increases the second phase of glucose-mediated insulin secretion by 30%, while **antipreptin Ig** infusion decreases the first and second phases of insulin secretion by 29 and 26% resp. These findings suggest that **preptin** is a physiol. amplifier of glucose-mediated insulin secretion.

IT 315197-75-2, **Preptin** (mouse)
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
 (**preptin** derived from proinsulin-like growth factor II (proIGF-II) is secreted from pancreatic islet β -cells and enhances insulin secretion)

RN 315197-75-2 HCPLUS
 CN L-Leucine, L- α -aspartyl-L-valyl-L-seryl-L-threonyl-L-seryl-L-glutaminyl-L-alanyl-L-valyl-L-leucyl-L-prolyl-L- α -aspartyl-L- α -aspartyl-L-phenylalanyl-L-prolyl-L-arginyl-L-tyrosyl-L-prolyl-L-valylglycyl-L-lysyl-L-phenylalanyl-L-phenylalanyl-L-glutaminyl-L-tyrosyl-L- α -aspartyl-L-threonyl-L-tryptophyl-L-arginyl-L-glutaminyl-L-seryl-L-alanylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

REFERENCE COUNT: 63 THERE ARE 63 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2000:911296 HCAPLUS
 DOCUMENT NUMBER: 134:66711
 TITLE: Peptides having **preptin** functionality and
 their use as drugs for increasing insulin secretion
 INVENTOR(S): Cooper, Garth James Smith; Buchanan, Christina Maree
 PATENT ASSIGNEE(S): N. Z.
 SOURCE: PCT Int. Appl., 50 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000078805	A1	20001228	WO 2000-NZ102	20000619
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2375207	AA	20001228	CA 2000-2375207	20000619
EP 1185558	A1	20020313	EP 2000-942575	20000619
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2003503019	T2	20030128	JP 2001-505563	20000619
AU 759203	B2	20030410	AU 2000-57178	20000619
US 2003050434	A1	20030313	US 2000-745078	20001220
US 2003166561	A1	20030904	US 2003-374624	20030224
PRIORITY APPLN. INFO.:			NZ 1999-336359	A 19990618
			WO 2000-NZ102	W 20000619
			US 2000-745078	B1 20001220

OTHER SOURCE(S): MARPAT 134:66711

AB The invention relates to a bioactive mammalian peptide. In particular, it relates to a peptide secreted by the pancreatic islet β -cell that stimulates insulin secretion, termed **preptin**. **Preptin** analogs, pharmaceutical compns. which contain **preptin** or its analogs and their use as medicaments are inter alia also provided. Isolated polynucleotides encoding human, rat, or mouse **preptin** or their analogs; vectors or cell lines expressing peptides having **preptin** functionality; antibodies binding **preptin** or its analogs and their use in immunoassays for determining **preptin** in biol. fluids are also claimed.

IT 315197-69-4, **Preptin** (human) 315197-73-0,
Preptin (rat) 315197-75-2, **Preptin** (mouse)
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (amino acid sequence; peptides having **preptin** functionality and their use as drugs for increasing insulin secretion)

RN 315197-69-4 HCAPLUS
 CN L-Leucine, L- α -aspartyl-L-valyl-L-seryl-L-threonyl-L-prolyl-L-prolyl-L-threonyl-L-valyl-L-leucyl-L-prolyl-L- α -aspartyl-L-asparaginyl-L-phenylalanyl-L-prolyl-L-arginyl-L-tyrosyl-L-prolyl-L-valylglycyl-L-lysyl-L-phenylalanyl-L-phenylalanyl-L-glutaminyl-L-tyrosyl-L- α -aspartyl-L-

threonyl-L-tryptophyl-L-lysyl-L-glutaminyL-seryl-L-threonyl-L-glutaminyL-L-arginyl- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 315197-73-0 HCPLUS

CN L-Leucine, L- α -aspartyl-L-valyl-L-seryl-L-threonyl-L-seryl-L-glutaminyL-alanyl-L-valyl-L-leucyl-L-prolyl-L- α -aspartyl-L-phenylalanyl-L-prolyl-L-arginyl-L-tyrosyl-L-prolyl-L-valylglycyl-L-lysyl-L-phenylalanyl-L-phenylalanyl-L-lysyl-L-phenylalanyl-L- α -aspartyl-L-threonyl-L-tryptophyl-L-arginyl-L-glutaminyL-seryl-L-alanylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 315197-75-2 HCPLUS

CN L-Leucine, L- α -aspartyl-L-valyl-L-seryl-L-threonyl-L-seryl-L-glutaminyL-alanyl-L-valyl-L-leucyl-L-prolyl-L- α -aspartyl-L-phenylalanyl-L-prolyl-L-arginyl-L-tyrosyl-L-prolyl-L-valylglycyl-L-lysyl-L-phenylalanyl-L-phenylalanyl-L-glutaminyL-tyrosyl-L- α -aspartyl-L-threonyl-L-tryptophyl-L-arginyl-L-glutaminyL-seryl-L-alanylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 314780-97-7, DNA (human *preptin* gene)

314780-98-8, DNA (rat *preptin* gene) 314780-99-9

, DNA (mouse *preptin* gene)

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(nucleotide sequence; peptides having *preptin* functionality and their use as drugs for increasing insulin secretion)

RN 314780-97-7 HCPLUS

CN DNA (human *preptin* gene) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 314780-98-8 HCPLUS

CN DNA (rat *preptin* gene) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 314780-99-9 HCPLUS

CN DNA (mouse *preptin* gene) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Kosar 10632366

```
=> => d stat que 18
L1      76 SEA FILE=REGISTRY ABB=ON  PLU=ON  DVSTPPTVLPDNFPRYPVGKFFQYDTWKQ
          STQRL|DVSTSQAVLPDDFPRYPVGKFFKFDTWRQSAGRL|DVSTSQAVLPDDFPRYPVGKFF
          QYDTWRQSAGRL/SQSP
L2      6 SEA FILE=REGISTRY ABB=ON  PLU=ON  PREPTIN/BI
L3      64 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L1
L4      4 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L2 OR ?PREPTIN?
L5      4 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L3 AND L4
L6      133626 SEA FILE=HCAPLUS ABB=ON  PLU=ON  ("BETA CELL PANCREATIC ISLET
          OF LANGERHANS"/CV OR "PANCREATIC ISLET OF LANGERHANS (L)
          B-CELL"/CV) OR BETA(W) CELL OR ?PANCREA? OR ISLET OR
          LANGERHAN?
L7      11 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L3 AND L6
L8      8 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L7 NOT L5
```

=>
=>

=> d ibib abs hitstr 18 1-8

L8 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005:527387 HCAPLUS
 DOCUMENT NUMBER: 143:58021
 TITLE: Protein markers of cancers and their use in diagnosis
 and as targets for drug therapy
 INVENTOR(S): Reinhard, Christoph; Jefferson, Anne Bennett; Chan,
 Vivien W.; Kaufmann, Joerg; Xin, Hong; Kennedy, Giulia
 C.; Harrowe, Greg; Khoja, Hamiduddin; Shyamala,
 Venkatakrishna
 PATENT ASSIGNEE(S): Chiron Corporation, USA
 SOURCE: U.S. Pat. Appl. Publ., 206 pp., Cont.-in-part of U.S.
 Ser. No. 763,692.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 6
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005130926	A1	20050616	US 2004-977087	20041028
US 6566063	B1	20030520	US 2000-570593	20000512
US 6743602	B1	20040601	US 2000-626301	20000725
US 2003045491	A1	20030306	US 2002-81119	20020221
US 2005059801	A1	20050317	US 2003-698959	20031030
US 2004265928	A1	20041230	US 2004-763692	20040122
PRIORITY APPLN. INFO.:				
			US 1998-107112P	P 19981104
			US 1999-114856P	P 19990106
			US 1999-134112P	P 19990514
			US 1999-145612P	P 19990726
			US 1999-148936P	P 19990813
			US 1999-433360	B1 19991103
			US 2000-570593	A1 20000512
			US 2000-626301	A1 20000725
			US 2001-271254P	P 20010221
			US 2002-81119	A2 20020221
			US 2003-360848	B2 20030206
			US 2003-698959	A2 20031030
			US 2004-763692	A2 20040122
			US 2001-289813P	P 20010223

AB Proteins that show altered levels as a result of changes in gene expression in neoplasm are identified for use in the diagnosis and prognosis of cancers and as drug targets for anticancer drugs. The proteins are a threonine tyrosine kinase (TTK), GSEF (gland-specific ETS factor), HX2004-6, and the receptor VSHK-1. These genes were identified by anal. of gene expression in a number of human cancers. Antisense inhibition of TTK gene expression in cultured cells led to a slowing cell proliferation and added to the cytotoxic effect of cisplatin without showing specific sensitizing cells to it.

IT 853830-43-0
 RL: PRP (Properties)
 (unclaimed protein sequence; protein markers of cancers and their use in diagnosis and as targets for drug therapy)
 RN 853830-43-0 HCAPLUS
 CN 38: PN: US20050130926 SEQID: 38 unclaimed protein (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L8 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004:681680 HCAPLUS
 DOCUMENT NUMBER: 141:200162
 TITLE: Mitochondrial malate dehydrogenase DNA fragmentation activator fragment and related conjugated proteins and antibodies for cancer therapy
 INVENTOR(S): Wright, Susan C.; Lerrick, James W.; Nock, Steffen R.; Wilson, David S.
 PATENT ASSIGNEE(S): Palo Alto Institute of Molecular Medicine, USA
 SOURCE: PCT Int. Appl., 225 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004070012	A2	20040819	WO 2004-US2974	20040202
WO 2004070012	A3	20060330		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2004209644	A1	20040819	AU 2004-209644	20040202
CA 2514841	AA	20040819	CA 2004-2514841	20040202
US 2004191843	A1	20040930	US 2004-770668	20040202
EP 1590440	A2	20051102	EP 2004-707424	20040202
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRIORITY APPLN. INFO.:				
		US 2003-444191P	P	20030203
		US 2003-460855P	P	20030408
		US 2004-770668	A	20040202
		WO 2004-US2974	W	20040202

AB The invention provides compns. comprising amino acid sequences that have cell killing activity, nucleic acid sequences encoding them, antibodies that specifically bind with them, and methods of using these compns. for increasing and/or reducing cell death, detecting cell death, diagnosing diseases associated with altered cell death, and methods for identifying test agents that alter cell death. More particularly, the invention provides an activator of DNA fragmentation (ADF), a C-terminal fragment of mitochondrial MDH (malate dehydrogenase), which can induce DNA fragmentation by activating nuclease endogenous to normal nuclei. The invention also provides a conjugate comprising a cell death-inducing mol. (such as ADF) and a cell mol.-recognizing compound, and use of said conjugate in killing cancer cells. Specifically, the invention relates that conjugate can be composed of said ADF and/or other mitochondrial/non-mitochondrial cell death-inducing proteins (such as Htra/Omi, apoptosis inducing factor, Smac/DIABLO, EndoG, Nix, Nip3, CIDE-B, gelsolin, Bcl-2, Bax, Bad, Bid, caspase-activated DNase, DNase I or DNase II), and that cell mol.-recognizing compds. can include antibodies or growth factors. In particular embodiments, recombinant ADF proteins, ADF-Ant (antennapedia) and rADF-bFGF, are shown to be cytotoxic to a variety to tumor cell types, and even drug-resistant cancer cell

Kosar 10632366

lines.
IT 742221-41-6
RL: PRP (Properties)
(unclaimed protein sequence; mitochondrial malate dehydrogenase DNA
fragmentation activator fragment and related conjugated proteins and
antibodies for cancer therapy)
RN 742221-41-6 HCAPLUS
CN 46: PN: WO2004070012 SEQID: 46 unclaimed protein (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L8 ANSWER 3 OF 8 HCPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004:355655 HCPLUS
 DOCUMENT NUMBER: 140:351720
 TITLE: Differentially expressed nucleic acids and their encoded proteins and their uses for the diagnosis and treatment of tumor
 INVENTOR(S): Wu, Thomas D.; Zhang, Zemin; Zhou, Yan
 PATENT ASSIGNEE(S): Genentech, Inc., USA
 SOURCE: PCT Int. Appl., 7273 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004030615	A2	20040415	WO 2003-XA28547	20030929
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2004030615	A2	20040415	WO 2003-US28547	20030929
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2002-414971P P 20021002
 WO 2003-US28547 A 20030929

AB The present invention provides a large number of specific cDNA sequences which are upregulated in certain tumor tissues as compared to their normal tissue counterparts and therefore useful for the diagnosis and treatment of tumor in mammals. An expressed sequence tag (EST) DNA database was searched and interesting EST sequences identified by GEPIS (gene expression profiling in silico), a bioinformatics tool that characterizes genes of interest for new cancer therapeutic targets. Using this type of screening bioinformatics, various tumor-associated antigenic target (TAT) proteins (and their encoding nucleic acid mols) were identified as being significantly overexpressed in particular type of cancer or certain cancers as compared to other cancers and/or normal non-cancerous tissues.

IT 680884-69-9P, Tumor-associated antigen PRO124 (human)
 RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)

(amino acid sequence; differentially expressed nucleic acids and their encoded proteins and their uses for the diagnosis and treatment of tumor)

Kosar 10632366

RN 680884-69-9 HCPLUS

CN Tumor-associated antigen PRO124 (human) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L8 ANSWER 4 OF 8 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2003:951153 HCAPLUS
 DOCUMENT NUMBER: 140:26911
 TITLE: Human insulin-like growth factor receptor-specific human neutralizing monoclonal antibodies for treating and preventing cancer
 INVENTOR(S): Wang, Yan; Greenberg, Robert; Presta, Leonard; Pachter, Jonathan A.; Hailey, Judith; Brams, Peter; Williams, Denise; Srinivasan, Mohan; Feingersh, Diane
 PATENT ASSIGNEE(S): Schering Corporation, USA
 SOURCE: PCT Int. Appl., 144 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003100008	A2	20031204	WO 2003-US16283	20030522
WO 2003100008	A3	20040408		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NI, NO, NZ, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, US, UZ, VC, VN, YU, ZA, ZM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2484000	AA	20031204	CA 2003-2484000	20030522
US 2004018191	A1	20040129	US 2003-443466	20030522
EP 1506286	A2	20050216	EP 2003-731338	20030522
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005527222	T2	20050915	JP 2004-508250	20030522
CN 1671837	A	20050921	CN 2003-817686	20030522
NO 2004005645	A	20041223	NO 2004-5645	20041223
PRIORITY APPLN. INFO.:			US 2002-383459P	P 20020524
			US 2002-393214P	P 20020702
			US 2002-436254P	P 20021223
			WO 2003-US16283	W 20030522

AB The present invention includes transgenic non-human animal-produced fully human, neutralizing, monoclonal antibodies against human insulin-like growth factor receptor-I or IGFR1. The antibodies are useful for treating or preventing cancer in a subject. Also included are methods of using and producing the antibodies of the invention.

IT 628822-82-2

RL: PRP (Properties)
 (unclaimed protein sequence; human insulin-like growth factor receptor-specific human neutralizing monoclonal antibodies for treating and preventing cancer)

RN 628822-82-2 HCAPLUS

CN 13: PN: WO03100008 SEQID: 21 unclaimed protein (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L8 ANSWER 5 OF 8 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2003:942767 HCAPLUS
 DOCUMENT NUMBER: 140:40262
 TITLE: Genes expressed in atherosclerotic tissue and their use in diagnosis and pharmacogenetics
 INVENTOR(S): Nevins, Joseph; West, Mike; Goldschmidt, Pascal
 PATENT ASSIGNEE(S): Duke University, USA
 SOURCE: PCT Int. Appl., 408 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003091391	A2	20031106	WO 2002-XB38221	20021112
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2003091391	A2	20031106	WO 2002-US38221	20021112
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 2002-374547P	P 20020423
			US 2002-420784P	P 20021024
			US 2002-421043P	P 20021025
			US 2002-424680P	P 20021108
			WO 2002-US38221	A 20021112

AB Genes whose expression is correlated with an determinant of an atherosclerotic phenotype are provided. Also provided are methods of using the subject atherosclerotic determinant genes in diagnosis and treatment methods, as well as drug screening methods. In addition, reagents and kits thereof that find use in practicing the subject methods are provided. Also provided are methods of determining whether a gene is correlated with a disease phenotype, where correlation is determined using a Bayesian anal. [This abstract record is one of three records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].

IT 481287-00-7, Protein (human gene IGF2)
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
 (amino acid sequence; genes expressed in atherosclerotic tissue and their use in diagnosis and pharmacogenetics)

RN 481287-00-7 HCAPLUS
 CN Protein (human gene IGF2) (9CI) (CA INDEX NAME)

Kosar 10632366

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L8 ANSWER 6 OF 8 HCPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2003:875393 HCPLUS
 DOCUMENT NUMBER: 139:363045
 TITLE: Genes expressed in atherosclerotic tissue and their use in diagnosis and pharmacogenetics
 INVENTOR(S): Nevins, Joseph; West, Mike; Goldschmidt, Pascal
 PATENT ASSIGNEE(S): Duke University, USA
 SOURCE: PCT Int. Appl., 408 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003091391	A2	20031106	WO 2002-US38221	20021112
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2003091391	A2	20031106	WO 2002-XA38221	20021112
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2003091391	A2	20031106	WO 2002-XB38221	20021112
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2002364707	A1	20031110	AU 2002-364707	20021112
US 2003224383	A1	20031204	US 2002-291885	20021112
EP 1578918	A2	20050928	EP 2002-807324	20021112
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
PRIORITY APPLN. INFO.:				
		US 2002-374547P	P	20020423
		US 2002-420784P	P	20021024
		US 2002-421043P	P	20021025
		US 2002-424680P	P	20021108
		WO 2002-US38221	A	20021112

AB Genes whose expression is correlated with an determinant of an atherosclerotic phenotype are provided. Also provided are methods of using the subject atherosclerotic determinant genes in diagnosis and treatment methods, as well as drug screening methods. In addition, reagents

and kits thereof that find use in practicing the subject methods are provided. Also provided are methods of determining whether a gene is correlated

with a disease phenotype, where correlation is determined using a Bayesian anal.

IT 481287-00-7, Protein (human gene IGF2)

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(amino acid sequence; genes expressed in atherosclerotic tissue and their use in diagnosis and pharmacogenetics)

RN 481287-00-7 HCPLUS

CN Protein (human gene IGF2) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L8 ANSWER 7 OF 8 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2003:442069 HCAPLUS
 DOCUMENT NUMBER: 139:18315
 TITLE: Gene expression profiles useful for methods of diagnosis of cancer and screening for modulators of cancer
 INVENTOR(S): Afar, Daniel; Aziz, Natasha; Ginsburg, Wendy M.; Gish, Kurt C.; Glynne, Richard; Hevezi, Peter A.; Mack, David H.; Murray, Richard; Watson, Susan R.; Wilson, Keith E.; Zlotnik, Albert
 PATENT ASSIGNEE(S): Eos Biotechnology, Inc., USA
 SOURCE: PCT Int. Appl., 1385 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 38
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003042661	A2	20030522	WO 2002-XK36810	20021113
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2003042661	A2	20030522	WO 2002-US36810	20021113
WO 2003042661	C1	20031016		
WO 2003042661	A3	20041028		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004197325	A1	20041007	US 2003-741657	20031219
PRIORITY APPLN. INFO.:				
US 2001-350666P P 20011113				
US 2001-332464P P 20011121				
US 2001-334393P P 20011129				
US 2001-335394P P 20011203				
US 2001-340376P P 20011214				
US 2002-347211P P 20020108				
US 2002-347349P P 20020110				
US 2002-356714P P 20020213				
US 2002-359077P P 20020220				
US 2002-368809P P 20020329				
US 2002-370110P P 20020404				
US 2002-372246P P 20020412				
US 2002-386614P P 20020605				
US 2002-396839P P 20020716				
US 2002-397775P P 20020722				

US 2002-397845P	P 20020722
US 2002-409450P	P 20020909
WO 2002-US36810	W 20021113
US 2002-173999	A 20020617
US 2002-435618P	P 20021220

AB Described herein are genes whose expression are up-regulated or down-regulated in specific cancers or other diseases, or are otherwise regulated in disease. Mol. profiles of various normal and cancerous tissues were determined and analyzed using the Affymetrix/Eos Hu3 GeneChip array comprising .apprx.58,680 probesets. Related methods and compns. that can be used for diagnosis, prognosis, and treatment of those medical conditions are disclosed. Also described herein are methods that can be used to identify modulators of these selected conditions. [This abstract record is one of twelve records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].

IT 537723-29-8
RL: DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study);
USES (Uses)
(amino acid sequence; gene expression profiles useful for methods of
diagnosis of cancer and screening for modulators of cancer)

RN 537723-29-8 HCPLUS

CN Tumor-associated protein (human clone WO03042661-SEQID-199) (9CI) (CA
INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L8 ANSWER 8 OF 8 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2000:824291 HCAPLUS
 DOCUMENT NUMBER: 134:21425
 TITLE: Protection of endogenous therapeutic peptides from
 peptidase activity through conjugation to blood
 components
 INVENTOR(S): Bridon, Dominique P.; Ezrin, Alan M.; Milner, Peter
 G.; Holmes, Darren L.; Thibaudeau, Karen
 PATENT ASSIGNEE(S): Conjuchem, Inc., Can.
 SOURCE: PCT Int. Appl., 733 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 5
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000069900	A2	20001123	WO 2000-US13576	20000517
WO 2000069900	A3	20010215		
WO 2000069900	C2	20020704		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2373252	AA	20001123	CA 2000-2373252	20000517
CA 2373680	AA	20001123	CA 2000-2373680	20000517
CA 2499211	AA	20001123	CA 2000-2499211	20000517
CA 2501421	AA	20001123	CA 2000-2501421	20000517
CA 2505617	AA	20001123	CA 2000-2505617	20000517
WO 2000070665	A2	20001123	WO 2000-IB763	20000517
WO 2000070665	A3	20010419		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1105409	A2	20010613	EP 2000-936023	20000517
EP 1105409	B1	20060301		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY				
EP 1171582	A2	20020116	EP 2000-929748	20000517
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
EP 1264840	A1	20021211	EP 2002-14617	20000517
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003500341	T2	20030107	JP 2000-619018	20000517
JP 2003508350	T2	20030304	JP 2000-618316	20000517
AU 765753	B2	20030925	AU 2000-51393	20000517
EP 1591453	A1	20051102	EP 2005-105384	20000517
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, LT, LV, FI, RO, MK, CY, AL				
EP 1598365	A1	20051123	EP 2005-105387	20000517
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
IE, SI, LT, LV, FI, RO, MK, CY, AL				
EP 1623994	A2	20060208	EP 2005-108328	20000517
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
IE, SI, LT, LV, FI, RO, MK, CY, AL				
AT 318835	E	20060315	AT 2000-936023	20000517
US 6849714	B1	20050201	US 2000-623548	20000905
US 6514500	B1	20030204	US 2000-657332	20000907
ZA 2001006676	A	20020719	ZA 2001-6676	20010814
ZA 2001009110	A	20020613	ZA 2001-9110	20011105
US 2003108567	A1	20030612	US 2002-287892	20021104
US 6821949	B2	20041123		
US 2003108568	A1	20030612	US 2002-288340	20021104
US 6887849	B2	20050503		
US 2004127398	A1	20040701	US 2003-722733	20031125
US 2004138100	A1	20040715	US 2003-723099	20031125
US 2005176641	A1	20050811	US 2005-40810	20050121
US 2005176643	A1	20050811	US 2005-67556	20050225
JP 2005263807	A2	20050929	JP 2005-115175	20050412
JP 2005239736	A2	20050908	JP 2005-140407	20050512
JP 2005255689	A2	20050922	JP 2005-151458	20050524
US 2006009377	A1	20060112	US 2005-170967	20050629
US 2006058235	A1	20060316	US 2005-215967	20050830

PRIORITY APPLN. INFO.:

US 1999-134406P	P	19990517
US 1999-153406P	P	19990910
US 1999-159783P	P	19991015
CA 2000-2363712	A3	20000517
CA 2000-2373680	A3	20000517
EP 2000-932570	A3	20000517
EP 2000-936023	A3	20000517
JP 2000-618316	A3	20000517
JP 2000-618327	A3	20000517
WO 2000-IB763	W	20000517
WO 2000-US13576	W	20000517
US 2000-623548	A1	20000905
US 2000-657276	A2	20000907
US 2000-657332	A3	20000907
US 2002-400199P	P	20020731
US 2002-400413P	P	20020731
US 2002-288340	A1	20021104
WO 2003-CA1097	W	20030729
US 2003-471348	B1	20030908
US 2003-722733	A1	20031125
US 2005-40810	A2	20050121
US 2005-170967	A1	20050629

AB A method for protecting a peptide from peptidase activity in vivo, the peptide being composed of between 2 and 50 amino acids and having a C-terminus and an N-terminus and a C-terminus amino acid and an N-terminus amino acid is described. In the first step of the method, the peptide is modified by attaching a reactive group to the C-terminus amino acid, to the N-terminus amino acid, or to an amino acid located between the N-terminus and the C-terminus, such that the modified peptide is capable of forming a covalent bond in vivo with a reactive functionality on a blood component. The solid phase peptide synthesis of a number of derivs. with 3-maleimidopropionic acid (3-MPA) is described. In the next step, a covalent bond is formed between the reactive group and a reactive functionality on a blood component to form a peptide-blood component conjugate, thereby protecting said peptide from peptidase activity. The

Kosar 10632366

final step of the method involves the analyzing of the stability of the peptide-blood component conjugate to assess the protection of the peptide from peptidase activity. Thus, the percentage of a K5 kringle peptide (Pro-Arg-Lys-Leu-Tyr-Asp-Lys-NH₂) conjugated to human serum albumin via MPA remained relatively constant through a 24-h plasma assay in contrast to unmodified K5 which decreased to 9% of the original amount of K5 in only 4 h in plasma.

IT 309257-18-9

RL: PRP (Properties)

(unclaimed protein sequence; protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components)

RN 309257-18-9 HCPLUS

CN 202: PN: WO0069900 SEQID: 381 unclaimed protein (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

```
=> => d stat que l12
L1      76 SEA FILE=REGISTRY ABB=ON  PLU=ON  DVSTPPPTVLPDNFPRYPVGKFFQYDTWKQ
          STQRL|DVSTSQAVLPDDFPRYPVGKFFKFDTWRQSAGRL|DVSTSQAVLPDDFPRYPVGKFF
          QYDTWRQSAGRL/SQSP
L2      6 SEA FILE=REGISTRY ABB=ON  PLU=ON  PREPTIN/BI
L3      64 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L1
L4      4 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L2 OR ?PREPTIN?
L5      4 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L3 AND L4
L6      133626 SEA FILE=HCAPLUS ABB=ON  PLU=ON  ("BETA CELL PANCREATIC ISLET
          OF LANGERHANS"/CV OR "PANCREATIC ISLET OF LANGERHANS (L)
          B-CELL"/CV) OR BETA(W) CELL OR ?PANCREA? OR ISLET OR
          LANGERHAN?
L7      11 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L3 AND L6
L8      8 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L7 NOT L5
L9      1400588 SEA FILE=HCAPLUS ABB=ON  PLU=ON  CELL(L) (FUNCT? OR IMPROV? OR
          PROLIFER? OR INCREAS? OR REGULAT? OR GROWTH OR MAINT?)
L10     18 SEA FILE=HCAPLUS ABB=ON  PLU=ON  (L9 AND L3) NOT (L5 OR L8)
L11     21 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L3(L) (?INSUL? OR ?DIABET? OR
          ?THERAP? OR ?PREVENT?)
L12     25 SEA FILE=HCAPLUS ABB=ON  PLU=ON  (L10 OR L11) NOT (L5 OR L8)
```

```
=>
=>
```

```
=> d ibib abs hitstr l12 1-25
```

L12 ANSWER 1 OF 25 HCPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005:1335397 HCPLUS
 DOCUMENT NUMBER: 144:64367
 TITLE: Mannose-6-phosphate-independent targeting of therapeutic proteins to the lysosome using fusion proteins insulin-like growth factor II
 INVENTOR(S): Lebowitz, Jonathan H.; Beverley, Stephen M.; Sly, William S.
 PATENT ASSIGNEE(S): Symbiontis, Inc., USA
 SOURCE: U.S. Pat. Appl. Publ., 87 pp., Cont.-in-part of U.S. Ser. No. 272,531.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 7
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005281805	A1	20051222	US 2004-981267	20041103
US 2004006008	A1	20040108	US 2002-272483	20021016
US 2004005309	A1	20040108	US 2002-272531	20021016
WO 2003102583	A1	20031211	WO 2003-US17211	20030529
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:				
US 2002-384452P P 20020529				
US 2002-386019P P 20020605				
US 2002-408816P P 20020906				
US 2002-272483 A2 20021016				
US 2002-272531 A2 20021016				
US 2003-445734P P 20030206				
WO 2003-US17211 A2 20030529				
US 2003-516900P P 20031103				
US 2001-287531P P 20010430				
US 2001-304609P P 20010710				
US 2001-329461P P 20011015				
US 2002-351276P P 20020123				
US 2002-136841 A2 20020430				

AB Methods of targeting therapeutic proteins to the lysosome, e.g. in enzyme replacement therapy, that avoid the need to glycosylate the therapeutic protein are described. The method involves using insulin-like growth factor II (IGF-II) to target a fusion protein to the cation-independent mannose-6-phosphate receptor of the lysosome. This receptor shows a higher affinity for IGF-II than it does for mannose-6-phosphate and so can be used to target a relatively underglycosylated protein to the lysosome. As the primary function of the binding of IGF-II to the lysosomal receptor is commitment to proteolysis, there are no physiol. effects for the use of IGF-II as the carrier. The fusion protein also includes a targeting moiety that binds a receptor on an exterior surface of the cell, permitting proper subcellular localization of the targeted therapeutic upon internalization of the receptor. Fusion proteins of IGF-II and

Kosar 10632366

carbohydrases were manufactured by expression of the corresponding gene in Leishmani mexicana. They showed receptor-specific binding and retained enzymic activity.

IT 871755-52-1

RL: PRP (Properties)

(unclaimed protein sequence; mannose-6-phosphate-independent targeting of **therapeutic** proteins to the lysosome using fusion proteins insulin-like growth factor II)

RN 871755-52-1 HCAPLUS

CN 2: PN: US20050281805 SEQID: 2 unclaimed protein (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L12 ANSWER 2 OF 25 HCPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005:1223698 HCPLUS
 DOCUMENT NUMBER: 143:457991
 TITLE: Nucleic acids and their encoded polypeptides
 differentially regulated in preeclampsia and their
 detection in diagnostic kits and risk assessment
 INVENTOR(S): Labat, Ivan; Tang, Y. Tom; Stache-Crain, Birgit;
 Boyle, Bryan
 PATENT ASSIGNEE(S): Nuvelo, Inc., USA
 SOURCE: U.S. Pat. Appl. Publ., 358 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005255114	A1	20051117	US 2004-821234	20040407
PRIORITY APPLN. INFO.:			US 2003-462047P	P 20030407

AB Provided by the present invention are methods for treating and diagnosing preeclampsia, as well as kits for use in diagnosing patients with a higher risk of preeclampsia. Eight hundred fifty-two novel nucleic acids were obtained from several human normal and pre-eclamptic placental cDNA libraries using standard PCR, sequencing-by-hybridization sequence signature anal., and Sanger sequencing techniques. In some cases, the nucleic acids were assembled using sequences from one or more public databases, using a recursive algorithm to extend the seed EST into an extended assemblage, or RACE (rapid amplification of cDNA ends) to further extend the sequence in the 5' direction. The sequences are differentially regulated in pre-eclamptic placenta in comparison to normal placenta.

IT 869138-89-6
 RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(amino acid sequence; nucleic acids and their encoded polypeptides
 differentially regulated in preeclampsia and their detection in
 diagnostic kits and risk assessment)

RN 869138-89-6 HCPLUS

CN Preeclampsia-associated protein (human clone US20050255114-SEQID-971)
 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L12 ANSWER 3 OF 25 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005:1005893 HCAPLUS
 DOCUMENT NUMBER: 143:300322
 TITLE: Sequences for insulin-like growth factor-like (IGFL) proteins, IGFL variants and pseudogenes, antibodies thereof, and therapeutic and diagnostic uses
 INVENTOR(S): Emtage, Peter C. R.; Hu, Tianhua; Tang, Y. Tom
 PATENT ASSIGNEE(S): Nuvelo, Inc., USA
 SOURCE: U.S. Pat. Appl. Publ., 67 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005202479	A1	20050915	US 2005-49518	20050202
WO 2005091777	A2	20051006	WO 2005-US3374	20050202
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2004-548282P P 20040227
 AB The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to novel insulin-like growth factor-like (IGFL) proteins. Particularly, the present invention provides four IGFL polypeptides and polynucleotides (herein referred to as IGFL1-4), two IGFL variants, IGFL-2v and IGFL-4v, and two IGFL pseudogenes, IGFL-5 and IGFL-6 from human. The human IGFL gene family was localized to chromosome 19 within 19p13.3 band. The murine syntenic region XII on chromosome 7 contains single IGFL gene. Other aspects of the invention include vectors containing processes for producing novel IGFL polypeptides, and antibodies specific for such polypeptides.

IT 864396-45-2

RL: PRP (Properties)

(unclaimed protein sequence; sequences for insulin-like growth factor-like (IGFL) proteins, IGFL variants and pseudogenes, antibodies thereof, and therapeutic and diagnostic uses)

RN 864396-45-2 HCAPLUS

CN 14: PN: US20050202479 SEQID: 25 unclaimed protein (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L12 ANSWER 4 OF 25 HCPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004:718567 HCPLUS
 DOCUMENT NUMBER: 141:218948
 TITLE: Murine and human nucleic acids and encoded proteins as diagnostic and therapeutic targets in cancer
 INVENTOR(S): Morris, David W.; Morris, David W.; Malandro, Marc S.
 PATENT ASSIGNEE(S): Sagres Discovery, Inc., USA
 SOURCE: PCT Int. Appl., 310 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004074320	A2	20040902	WO 2004-US4730	20040217
WO 2004074320	C1	20041209		
WO 2004074320	A3	20050602		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004170982	A1	20040902	US 2003-367094	20030214
US 2004180344	A1	20040916	US 2003-388838	20030314
US 2004219528	A1	20041104	US 2003-417375	20030415
US 2005090434	A1	20050428	US 2003-461862	20030613
US 2005202442	A1	20050915	US 2003-737318	20031215
AU 2004213432	A1	20040902	AU 2004-213432	20040217
CA 2516128	AA	20040902	CA 2004-2516128	20040217
EP 1594893	A2	20051116	EP 2004-711933	20040217
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRIORITY APPLN. INFO.:			US 2003-367094	A 20030214
			US 2003-388838	A 20030314
			US 2003-417375	A 20030415
			US 2003-461862	A 20030613
			US 2003-663431	A 20030915
			US 2003-737318	A 20031215
			WO 2004-US4730	A 20040217

AB The present invention relates to novel sequences for use in detection, diagnosis, and treatment of cancers, especially lymphomas and leukemias, prostate cancer, and breast cancer. Tumors are induced in mice using either mouse mammary tumor virus (MMTV) which causes mammary adenocarcinomas, or murine leukemia virus (MLV) which causes a variety of different hematopoietic malignancies. Detection of elevated levels of cDNA associated with cancer was achieved by quant. RT-PCR and microarrays. The invention provides murine and human cancer-associated (CA) cDNA and genomic DNA sequences whose expression is associated with cancer. The present invention provides CA polypeptides associated with cancer that are present on the cell surface and present novel therapeutic targets against cancer. The present invention further provides diagnostic compns. and methods for the detection of cancer. The present invention provides monoclonal and polyclonal antibodies specific for the CA polypeptides. The present invention also provides diagnostic tools and therapeutic compns. and methods for screening, prevention, and treatment of cancer.

IT 746327-21-9 746327-26-4

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(amino acid sequence; murine and human nucleic acids and encoded proteins as diagnostic and therapeutic targets in cancer)

RN 746327-21-9 HCAPLUS

CN Tumor-associated protein (Mus clone mP15-022.1) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 746327-26-4 HCAPLUS

CN Tumor-associated protein (human clone hP15-022.2) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L12 ANSWER 5 OF 25 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004:677625 HCAPLUS
 DOCUMENT NUMBER: 141:219974
 TITLE: Full-length human cDNA and encoded protein sequences
 and their expression profiles
 INVENTOR(S): Isogai, Takao; Yamamoto, Junichi; Nishikawa, Tetsuo;
 Isono, Yuko; Sugiyama, Tomoyasu; Otsuki, Tetsuji;
 Wakamatsu, Ai; Ishii, Shizuko; Nagai, Keiichi; Irie,
 Ryotaro
 PATENT ASSIGNEE(S): Research Association for Biotechnology, Japan
 SOURCE: Eur. Pat. Appl., 9244 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1447413	A2	20040818	EP 2004-3145	20040212
EP 1447413	A3	20060104		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005006658	A2	20050113	JP 2004-232812	20040205
JP 2004261179	A2	20040924	JP 2004-37143	20040213
JP 2004357702	A2	20041224	JP 2004-139527	20040510
PRIORITY APPLN. INFO.: JP 2003-102207 A 20030214				
JP 2003-131452 A 20030509				

AB The invention provides 1995 human cDNAs with a high fullness ratio, and which encode full-length polypeptides, which were obtained by the oligo-capping method. None of the clones are identical to any known human mRNAs selected by searching 5'-end sequences and mRNA sequences with the annotation of "complete cds" in the GenBank and UniGene (Human) databases using BLAST homol. The full-length nucleotide sequences of the cDNA and amino acid sequences encoded by the nucleotide sequences were determined. Because the cDNA of the present invention are full-length and contain the translation start site, they provide information useful for analyzing the functions of the polypeptide. Gene expression profiles of the cDNA clones were studied by analyzing the large-scale cDNA database constructed based on the 5'-end nucleotide sequences, and gene functions were revealed by homol. searching and anal. of expression profiles in silico.

IT 746279-18-5, Protein (human clone BRACE3026345)
 RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); USES (Uses)
 (amino acid sequence; full-length human cDNA and encoded protein sequences and their expression profiles)
 RN 746279-18-5 HCAPLUS
 CN Protein (human clone BRACE3026345) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L12 ANSWER 6 OF 25 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004:240370 HCAPLUS
 DOCUMENT NUMBER: 140:269540
 TITLE: Antibodies that bind testis-specific insulin homolog polypeptides
 INVENTOR(S): Lok, Si; Conklin, Darrell C.; Lofton-Day, Catherine E.; Jaspers, Stephen R.; Stamm, Michael R.
 PATENT ASSIGNEE(S): ZymoGenetics, Inc., USA
 SOURCE: U.S., 33 pp., Cont.-in-part of U.S. Ser. No. 339,149, abandoned.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6709659	B1	20040323	US 2000-617389	20000717
US 5959075	A	19990928	US 1997-905267	19970801
JP 2002204698	A2	20020723	JP 2001-343542	19970801
US 6183991	B1	20010206	US 1999-314051	19990518
JP 2004073205	A2	20040311	JP 2003-304502	20030828
US 2004086509	A1	20040506	US 2003-700725	20031103
PRIORITY APPLN. INFO.:			US 1996-23213P	P 19960802
			US 1996-31592P	P 19961121
			US 1997-905267	A2 19970801
			US 1999-339149	B2 19990624
			JP 1998-508214	A3 19970801
			US 2000-617389	A3 20000717

AB The authors disclose testis-specific insulin homolog polypeptides and polynucleotides encoding them. The polypeptides and polynucleotides may be used for enhancing viability of cryopreserved sperm, for enhancing sperm motility, to enhance fertilization in methods of assisted reproduction, as contraceptives and other related uses.

IT 671823-44-2

RL: PRP (Properties)
 (unclaimed protein sequence; antibodies that bind testis-specific insulin homolog polypeptides)

RN 671823-44-2 HCAPLUS

CN 19: PN: US6709659 SEQID: 19 unclaimed protein (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 7 OF 25 HCPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004:59653 HCPLUS
 DOCUMENT NUMBER: 140:126701
 TITLE: Cellular gene expression monitoring for human
 cytomegalovirus (HCMV) infection for diagnostic and
 drug screening applications
 INVENTOR(S): Zhu, Hua; Gingeras, Thomas R.; Shenk, Thomas
 PATENT ASSIGNEE(S): Affymetrix, Inc., USA
 SOURCE: U.S. Pat. Appl. Publ., 26 pp., Cont. of U.S. Ser. No.
 377,907.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004014027	A1	20040122	US 2001-950024	20010912
US 6936416	B2	20050830		
US 2006003321	A1	20060105	US 2005-212601	20050829
PRIORITY APPLN. INFO.:			US 1999-377907	A1 19990820
			US 1998-97708P	P 19980821
			US 2001-950024	A3 20010912

AB Certain human genes have been found to be induced or repressed in host cells infected with HCMV. A large set of such genes has been identified. These have diagnostic use in determining the extent of tissue damage caused by the infection as well as in determining the stage of disease progression of the HCMV infection. Such genes are likely those involved in mediating the pathol. of the infected tissues. Thus by identifying agents which are able to reverse the induction or repression of such genes, one can find candidate therapeutic agents for use in treating and/or preventing HCMV-caused disease pathologies. Specifically disclosed are 258 mRNAs (with GenBank Accession Number provided) identified from microarray of about 6600 mRNA isolated from primary human fibroblast infected with HCMV strain AD169, whose levels are changed by a factor of 4 or more (124 increased, 134 decreased) in response to HCMV infection (after infection but before the onset of viral DNA replication). Several of these mRNAs are claimed to encode gene products that might play key roles in virus-induced pathogenesis, which include HLA-E, Ro/SSA, lipocortin-1, cPLA2, COX-2 and thrombospondin-1.

IT 481286-95-7

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
 (amino acid sequence; cellular gene expression monitoring for human
 cytomegalovirus (HCMV) infection for diagnostic and drug screening
 applications)

RN 481286-95-7 HCPLUS

CN Insulin-like growth factor (human gene IGF2) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L12 ANSWER 8 OF 25 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004:20321 HCAPLUS
 DOCUMENT NUMBER: 140:99586
 TITLE: Preparation of lysosome targeted therapeutic fusion
 proteins and use for treating metabolic diseases
 INVENTOR(S): Lebowitz, Jonathan H.; Beverley, Stephen M.
 PATENT ASSIGNEE(S): Symbiontics, Inc., USA
 SOURCE: U.S. Pat. Appl. Publ., 46 pp., Cont.-in-part of U.S.
 Ser. No. 136,841.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 7
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004006008	A1	20040108	US 2002-272483	20021016
US 2003082176	A1	20030501	US 2002-136841	20020430
US 2005281805	A1	20051222	US 2004-981267	20041103
PRIORITY APPLN. INFO.:			US 2001-287531P	P 20010430
			US 2001-304609P	P 20010710
			US 2001-329461P	P 20011015
			US 2002-351276P	P 20020123
			US 2002-136841	A2 20020430
			US 2002-384452P	P 20020529
			US 2002-386019P	P 20020605
			US 2002-408816P	P 20020906
			US 2002-272483	A2 20021016
			US 2002-272531	A2 20021016
			US 2003-445734P	P 20030206
			WO 2003-US17211	A2 20030529
			US 2003-516900P	P 20031103

AB The present invention provides the targeted therapeutics that localize to a specific subcellular compartment such as the lysosome to facilitates the treatment of metabolic diseases. The targeted therapeutics include a therapeutic agent and a targeting moiety that binds a receptor on an exterior surface of the cell, permitting proper subcellular localization of the targeted therapeutic upon internalization of the receptor. Specifically, the invention simplifies preparation of targeted protein therapeutics by reducing requirements for posttranslational or postsynthesis processing of the protein and permits targeting of a therapeutic to a lysosome in an mannose-6-phosphate-independent manner. Nucleic acids, cells, and methods relating to the practice of the invention are also provided.

IT 643773-30-2

RL: PRP (Properties)

(unclaimed protein sequence; preparation of lysosome targeted therapeutic fusion proteins and use for treating metabolic diseases)

RN 643773-30-2 HCAPLUS

CN 2: PN: US20040006008 SEQID: 2 unclaimed protein (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L12 ANSWER 9 OF 25 HCPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2003:972337 HCPLUS
 DOCUMENT NUMBER: 140:23197
 TITLE: Lysosome targeted therapeutic proteins
 INVENTOR(S): Lebowitz, Jonathan H.; Beverley, Stephen M.; Sly, William S.
 PATENT ASSIGNEE(S): Symbiontics, Inc., USA
 SOURCE: PCT Int. Appl., 137 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 7
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003102583	A1	20031211	WO 2003-US17211	20030529
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004005309	A1	20040108	US 2002-272531	20021016
CA 2487815	AA	20031211	CA 2003-2487815	20030529
AU 2003237314	A1	20031219	AU 2003-237314	20030529
EP 1514106	A1	20050316	EP 2003-736779	20030529
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006501158	T2	20060112	JP 2004-509417	20030529
US 2005281805	A1	20051222	US 2004-981267	20041103
PRIORITY APPLN. INFO.:			US 2002-384452P	P 20020529
			US 2002-386019P	P 20020605
			US 2002-408816P	P 20020906
			US 2002-272531	A 20021016
			US 2003-445734P	P 20030206
			US 2002-272483	A2 20021016
			WO 2003-US17211	W 20030529
			US 2003-516900P	P 20031103

AB Targeted therapeutics that localize to a specific subcellular compartment such as the lysosome are provided. The targeted therapeutics include a therapeutic agent and a targeting moiety that binds a receptor on an exterior surface of the cell, permitting proper subcellular localization of the targeted therapeutic upon internalization of the receptor. Nucleic acids, cells, and methods relating to the practice of the invention are also provided.

IT 632394-04-8

RL: PRP (Properties)
 (unclaimed protein sequence; lysosome targeted therapeutic proteins)

RN 632394-04-8 HCPLUS

CN 2: PN: WO03102583 SEQID: 2 unclaimed protein (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Kosar 10632366

L12 ANSWER 10 OF 25 HCPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2003:355709 HCPLUS
 DOCUMENT NUMBER: 138:335902
 TITLE: Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
 INVENTOR(S): Monahan, John E.; Gannavarapu, Manjula; Hoersch, Sebastian; Kamatkar, Shubhangi; Kovats, Steven G.; Meyers, Rachel E.; Morrisey, Michael P.; Olandt, Peter J.; Sen, Ami; Veiby, Petter Ole; Mills, Gordon B.; Bast, Robert C.; Lu, Karen; Schmandt, Rosemarie E.; Zhao, Xumei; Glatt, Karen
 PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc., USA
 SOURCE: U.S. Pat. Appl. Publ., 44 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003087250	A1	20030508	US 2002-97340	20020314
WO 2002071928	A2	20020919	WO 2002-US7826	20020314
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005214831	A1	20050929	US 2005-50926	20050204
PRIORITY APPLN. INFO.:			US 2001-276025P	P 20010314
			US 2001-276026P	P 20010314
			US 2001-311732P	P 20010810
			US 2001-323580P	P 20010919
			US 2001-324967P	P 20010926
			US 2001-325102P	P 20010926
			US 2001-325149P	P 20010926
			US 2002-97340	A1 20020314

AB The invention relates to newly discovered nucleic acid mols. and proteins associated with ovarian cancer. All OV markers and M352-M360 markers were identified by transcriptional profiling using mRNA from 9 normal ovarian epithelia, 11 stage I/II ovarian cancer tumors, and 25 stage III/IV tumors. Clones having expression ≥ 2 -fold higher in ovarian tumors as compared to their expression in non-ovarian tumor tissues in at least 4 tumor samples were selected. Addnl. Mxxx markers were identified by transcriptional profiling using mRNA from 67 ovarian tumors of various histotypes and stage and 96 non-ovarian tumor tissues including normal ovarian epithelium, benign conditions, other normal tissues, and other abnormal tissues. Clones having expression ≥ 3 -fold higher in at least 10% of ovarian tumors, as compared to their expression in non-ovarian tumor tissue, were designated as ovarian cancer specific markers. Clones were identified by BLAST anal., against both public and proprietary sequence databases, of EST sequences known to be associated with each clone. A total of 363 cDNA markers including their protein products are provided. Compns., kits, and methods for detecting, characterizing,

Kosar 10632366

preventing, and treating human ovarian cancers are provided.

IT 516534-81-9

RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (amino acid sequence; nucleic acid mols. and proteins for the identification, assessment, prevention, and therapy of ovarian cancer)

RN 516534-81-9 HCAPLUS

CN Somatomedin A (human clone OV58 gene IGF2) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L12 ANSWER 11 OF 25 HCPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2003:174470 HCPLUS
 DOCUMENT NUMBER: 138:217879
 TITLE: Tyrosine threonine kinase (TTK) in diagnosis and as a therapeutic target in cancer
 INVENTOR(S): Reinhard, Christoph; Jefferson, Anne B.; Chan, Vivien W.
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 79 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 6
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003045491	A1	20030306	US 2002-81119	20020221
US 2005058627	A1	20050317	US 2004-951389	20040927
US 2005059630	A1	20050317	US 2004-951406	20040927
US 2005063974	A1	20050324	US 2004-951477	20040927
US 2005130926	A1	20050616	US 2004-977087	20041028
PRIORITY APPLN. INFO.:				
			US 2001-289813P	P 20010223
			US 1998-107112P	P 19981104
			US 1999-114856P	P 19990106
			US 1999-134112P	P 19990514
			US 1999-145612P	P 19990726
			US 1999-148936P	P 19990813
			US 1999-433360	B1 19991103
			US 2000-570593	A1 20000512
			US 2000-626301	A1 20000725
			US 2001-271254P	P 20010221
			US 2002-81119	A3 20020221
			US 2003-360848	B2 20030206
			US 2003-698959	A2 20031030
			US 2004-763692	A2 20040122

AB The present invention provides methods for identification of cancerous cells by detection of expression levels of TTK, as well as diagnostic, prognostic and therapeutic methods that take advantage of the differential expression of these genes in mammalian cancer. Such methods can be useful in determining the ability of a subject to respond to a particular

therapy, e.g., as the basis of rational therapy. In addition, the invention provides assays for identifying pharmaceuticals that modulate activity of these genes in cancers in which these genes are involved, as well as methods of inhibiting tumor growth by inhibiting activity of TTK.

IT 500742-70-1

RL: PRP (Properties)
 (unclaimed protein sequence; tyrosine threonine kinase (TTK) in diagnosis and as a therapeutic target in cancer)

RN 500742-70-1 HCPLUS

CN 36: PN: US20030045491 SEQID: 38 unclaimed protein (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L12 ANSWER 12 OF 25 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2002:676033 HCAPLUS
 DOCUMENT NUMBER: 137:215235
 TITLE: Use of cDNA encoding protein threonine tyrosine kinase
 in diagnosis and therapy of colon and breast cancer
 INVENTOR(S): Reinhard, Christoph; Jefferson, Anne B.; Chan, Vivien
 W.
 PATENT ASSIGNEE(S): Chiron Corporation, USA
 SOURCE: PCT Int. Appl., 113 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 6
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002068444	A1	20020906	WO 2002-US5278	20020221
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2438092	AA	20020906	CA 2002-2438092	20020221
EP 1377596	A1	20040107	EP 2002-709637	20020221
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
CN 1492875	A	20040428	CN 2002-805272	20020221
JP 2004526716	T2	20040902	JP 2002-567954	20020221
NZ 527421	A	20050527	NZ 2002-527421	20020221
PRIORITY APPLN. INFO.:			US 2001-271254P	P 20010221
			WO 2002-US5278	W 20020221

AB The present invention provides methods for identification of cancerous cells by detection of expression levels of TTK, as well as diagnostic, prognostic and therapeutic methods that take advantage of the differential expression of these genes in mammalian cancer. Such methods can be useful in determining the ability of a subject to respond to a particular

therapy, e.g., as the basis of rational therapy. In addition, the invention provides assays for identifying pharmaceuticals that modulate activity of these genes in cancers in which these genes are involved, as well as methods of inhibiting tumor growth by inhibiting activity of TTK.

IT 454747-09-2

RL: PRP (Properties)
 (unclaimed protein sequence; use of cDNA encoding protein threonine tyrosine kinase in diagnosis and therapy of colon and breast cancer)

RN 454747-09-2 HCAPLUS

CN 38: PN: WO02068444 SEQID: 38 unclaimed protein (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 13 OF 25 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2001:816868 HCAPLUS
 DOCUMENT NUMBER: 135:353853
 TITLE: **Myocardial cell proliferation**
 -associated genes, sequences and their uses in drug screening, diagnosis and therapeutics for myocardial necrosis
 INVENTOR(S): Yamada, Yoji; Sekine, Susumu; Kikuchi, Yasuhiro; Sakurada, Kazuhiro
 PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 171 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001083705	A1	20011108	WO 2001-JP3700	20010427
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2407656	AA	20011108	CA 2001-2407656	20010427
EP 1283255	A1	20030212	EP 2001-926026	20010427
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2004005578	A1	20040108	US 2003-258666	20030409
PRIORITY APPLN. INFO.:			JP 2000-126741	A 20000427
			WO 2001-JP3700	W 20010427

AB This invention provides cDNA and protein sequences of 19 myocardial **cell proliferation** associated genes which are highly expressed in rat fetal heart. The genes were isolated from rat heart by differential hybridization. The invention also provides the gene bank search results for these genes. The sequences provided in this invention can be used in drug screening, diagnosis and therapeutics for myocardial necrosis.

IT 94046-85-2

RL: PRP (Properties)
 (unclaimed protein sequence; myocardial **cell proliferation**-associated genes, sequences and their uses in drug screening, diagnosis and therapeutics for myocardial necrosis)

RN 94046-85-2 HCAPLUS

CN Insulin-like growth factor II, prepro- (rat clone 30 reduced) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 14 OF 25 HCPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2001:371708 HCPLUS
 DOCUMENT NUMBER: 135:1955
 TITLE: Production of biologically active recombinant
 insulin-like growth factor II polypeptides
 INVENTOR(S): Wu, Jen-Leih; Chen, Jyh-Yih
 PATENT ASSIGNEE(S): Academia Sinica, Taiwan
 SOURCE: U.S., 17 pp., Cont.-in-part of U.S. Ser. No. 3,708.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6235874	B1	20010522	US 1999-383212	19990826
US 6010882	A	20000104	US 1998-3708	19980107
PRIORITY APPLN. INFO.:			US 1997-34736P	P 19970110
			US 1998-3708	A2 19980107

AB The present invention relates to the finding and construction of fish insulin-like growth factor II (IGF-II) cDNAs which can be cloned and expressed in cells. This invention also relates to the production of biol. active fish IGF-II polypeptides by a gene expression system using fish IGF-II cDNAs. The fish IGF-II cDNAs have 1977 bp which transcribe into a prepeptide (signal peptide), and B, C, A, D, E domain peptides. The fish mature IGF-II is a single polypeptide containing the NH₂-B-C-A-D-COOH domains. The mature IGF-II polypeptide is 7 kDa in weight and has 70 amino acids. The fish recombinant IGF-II cDNA can be cloned and expressed in *E. coli*, yeast, baculovirus, and fish cells. The isolated and purified IGF-II E domain peptide has mitogenic and anti-tumor activity.

IT 93927-44-7, Insulin-like growth factor II (rat
 E-peptide) 340836-88-6

RL: PRP (Properties)
 (unclaimed protein sequence; production of biol. active recombinant
 insulin-like growth factor II polypeptides)

RN 93927-44-7 HCPLUS

CN Insulin-like growth factor II (rat E-peptide) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 340836-88-6 HCPLUS

CN 14: PN: US6235874 FIGURE: 2B unclaimed protein (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 15 OF 25 HCPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2000:175965 HCPLUS
 DOCUMENT NUMBER: 132:219214
 TITLE: Method for studying protein interactions in vivo using
 luminescent resonance energy transfer
 INVENTOR(S): Szalay, Aladar A.; Wang, Yubao; Wang-Pruski, Gefu
 PATENT ASSIGNEE(S): Loma Linda University, USA
 SOURCE: PCT Int. Appl., 30 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000014271	A1	20000316	WO 1999-US20207	19990902
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2341314	AA	20000316	CA 1999-2341314	19990902
AU 9958056	A1	20000327	AU 1999-58056	19990902
AU 752675	B2	20020926		
EP 1109931	A1	20010627	EP 1999-945460	19990902
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002524087	T2	20020806	JP 2000-569011	19990902
PRIORITY APPLN. INFO.:			US 1998-99068P	P 19980903
			US 1999-135835P	P 19990524
			WO 1999-US20207	W 19990902

AB A method for determining whether a first protein interacts with a second protein

within a living cell is disclosed. The method comprises providing the first protein complexed to a donor luciferase and the second protein complexed to an acceptor fluorophore within the cell. The complexed first protein and the complexed second protein are allowed to come into proximity to each other within the cell. Then, any fluorescence from the acceptor fluorophore resulting from luminescence resonance energy transfer from the donor luciferase is detected, where fluorescence from the acceptor fluorophore indicates that the first protein has interacted with the second protein. The Renilla luciferase cDNA was fused to IGF-BP 6 cDNA and humanized green fluorescent protein cDNA was fused to IGF-II cDNA. COS-7 cells were transfected with the fused cDNAs and protein interactions were detected by spectrofluorometry.

IT 93052-02-9P, Insulin-like growth factor II,
 prepro- (human reduced)
 RL: BPN (Biosynthetic preparation); PRP (Properties); BIOL (Biological study); PREP (Preparation)
 (amino acid sequence; method for studying protein interactions in vivo using luminescent resonance energy transfer)
 RN 93052-02-9 HCPLUS
 CN Insulin-like growth factor II, prepro- (human reduced) (9CI) (CA INDEX NAME)

Kosar 10632366

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 16 OF 25 HCPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2000:10565 HCPLUS
 DOCUMENT NUMBER: 132:74537
 TITLE: cDNA sequence of tilapia insulin-like growth factor-II
 and production of biol. active recombinant polypeptides
 INVENTOR(S): Wu, Jen-Leih; Chen, Jyh-Yih; Chang, Chi-Yyao
 PATENT ASSIGNEE(S): Academia Sinica, Taiwan
 SOURCE: U.S., 16 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6010882	A	20000104	US 1998-3708	19980107
TW 554044	B	20030921	TW 1998-87100186	19980108
US 6235874	B1	20010522	US 1999-383212	19990826
PRIORITY APPLN. INFO.:			US 1997-34736P	P 19970110
			US 1998-3708	A2 19980107

AB The present invention relates to the finding and construction of fish insulin-like growth factor II (IGF-II) cDNAs which can be cloned and expressed in cells. This invention also relates to the production of biol. active fish IGF-II polypeptides by a gene expression system using fish IGF-II cDNAs. The fish IGF-II cDNAs have 1971 bp which transcribe into a signal peptide, and B, C, A, D, E domain peptides. Tilapia prepro-IGF-II polypeptide of 215 amino acids shares homol. with rainbow trout IGF-II. The mature IGF-II polypeptide has 70 amino acids. The fish recombinant IGF-II cDNA can be cloned and expressed in E. coli, yeast, baculovirus, and fish cells.

IT 253578-19-7 253578-20-0

RL: PRP (Properties)
 (unclaimed protein sequence; cDNA sequence of tilapia insulin-like growth factor-II and production of biol. active recombinant polypeptides)

RN 253578-19-7 HCPLUS

CN 14: PN: US6010882 FIGURE: 2 unclaimed protein (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 253578-20-0 HCPLUS

CN 15: PN: US6010882 FIGURE: 2 unclaimed protein (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 17 OF 25 HCPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1992:484401 HCPLUS
DOCUMENT NUMBER: 117:84401
TITLE: Structure and expression of insulin-like growth factor
II gene of the rat
AUTHOR(S): Yamamoto, Mikio
CORPORATE SOURCE: Boei Med. Coll., Tokorosawa, Japan
SOURCE: Boei Ika Daigakko Zasshi (1990), 15(3), 119-29
CODEN: BIDZDQ; ISSN: 0385-1796
DOCUMENT TYPE: Journal
LANGUAGE: Japanese

AB The insulin-like growth factors (IGF) constitute a family of proteins with insulin-like and growth stimulating properties. The entire genomic and cDNA structures of the rat IGF II (rIGF II) and its expression patterns were elucidated. The rIGF II gene is unique, but has very complex transcriptional features because of the presence of more than 4 alternative promoters together with more than 10 polyadenylation sites. Although these promoters appear to be regulated co-operatively in normal tissues, they can also be regulated independently, as evidenced by the results obtained from tumor cells, where one promoter is enhanced, while the other is suppressed. From the nucleotide sequence determination of the entire 36 Kb genomic region covering the whole

rIGF II gene region containing all exons and introns and intergenic region up to the 5'-adjacent insulin gene, interesting structural features including regional multiplications became apparent especially in the intergenic region.

IT 94046-85-2 96162-27-5
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence of, complete)

RN 94046-85-2 HCPLUS

CN Insulin-like growth factor II, prepro- (rat clone 30 reduced) (9CI) (CA
INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 96162-27-5 HCPLUS

CN Insulin-like growth factor II, pro- (rat clone 30 reduced) (9CI) (CA
INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L12 ANSWER 18 OF 25 HCPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1989:206856 HCPLUS
DOCUMENT NUMBER: 110:206856
TITLE: Isolation of an insulin-like growth factor II cDNA
with a unique 5' untranslated region from human
placenta
AUTHOR(S): Shen, Shu Jane; Daimon, Makoto; Wang, Chun Yeh;
Jansen, Maarten; Ilan, Judith
CORPORATE SOURCE: Dep. Reprod. Biol., Case Western Reserve Univ.,
Cleveland, OH, 44106, USA
SOURCE: Proceedings of the National Academy of Sciences of the
United States of America (1988), 85(6), 1947-51
CODEN: PNASA6; ISSN: 0027-8424
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Human insulin-like growth factor II (IGF-II) cDNA from a
placental library was isolated and sequenced. The 5' untranslated region
(5'-UTR) sequence of this cDNA differs completely from that of adult human
liver and has considerable base sequence identity to the same region of an
IGF-II cDNA of a rat liver cell line, BRL-3A. Human placental
poly(A)+ RNA was probed with either the 5'-UTR of the isolated human
placental IGF-II cDNA or the 5'-UTR of the IGF-II cDNA obtained from adult
human liver. No transcripts were detected by using the 5'-UTR of the
adult liver IGF-II as the probe. In contrast, 3 transcripts of 6.0, 3.2,
and 2.2 kilobases were detected by using the 5'-UTR of the placental
IGF-II cDNA as the probe or the probe from the coding sequence. A 4th
IGF-II transcript of 4.9 kilobases presumably containing a 5'-UTR consisting
of a base sequence dissimilar to that of either IGF-II 5'-UTR was
apparent. Therefore, IGF-II transcripts detected may be products of
alternative splicing as their 5'-UTR sequence is contained within the
human IGF-II gene or they may be a consequence of alternative promoter
utilization in placenta.

IT 93052-02-9
RL: PRP (Properties)
(amino acid sequence of)
RN 93052-02-9 HCPLUS
CN Insulin-like growth factor II, prepro- (human reduced) (9CI) (CA INDEX
NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

Kosar 10632366

L12 ANSWER 19 OF 25 HCPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1988:432986 HCPLUS
DOCUMENT NUMBER: 109:32986
TITLE: Tissue-specific expression of insulin-like growth
factor II mRNAs with distinct 5' untranslated regions
[Erratum to document cited in CA107(21):192128v]
AUTHOR(S): Irminger, Jean Claude; Rosen, Kenneth M.; Humbel, Rene
E.; Villa-Komaroff, Lydia
CORPORATE SOURCE: Dep. Biochem., Univ. Zurich, Zurich, 8057, Switz.
SOURCE: Proceedings of the National Academy of Sciences of the
United States of America (1988), 85(4), 1070
CODEN: PNASA6; ISSN: 0027-8424
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Diagrams within Figure 4 were reversed in the original article. The error
was not reflected in the abstract or the index entries.
IT 93052-02-9
RL: PRP (Properties)
(amino acid sequence of (Erratum))
RN 93052-02-9 HCPLUS
CN Insulin-like growth factor II, prepro- (human reduced) (9CI) (CA INDEX
NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L12 ANSWER 20 OF 25 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1988:125844 HCAPLUS
DOCUMENT NUMBER: 108:125844
TITLE: Human insulin-like growth factor I and II messenger
RNA: isolation of complementary DNA and analysis of
expression
AUTHOR(S): Rall, Leslie B.; Scott, James; Bell, Graeme I.
CORPORATE SOURCE: Chiron Corp., Emeryville, CA, 94608, USA
SOURCE: Methods in Enzymology (1987), 146(Pept. Growth
Factors, Pt. A), 239-48
CODEN: MENZAU; ISSN: 0076-6879
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The isolation of mRNA from tissues and cultured **cells** is
described along with the preparation and isolation of cDNAs encoding
insulin-like **growth** factors (IGF) and their use in anal. of RNA
preps. for IGF-I and IGF-II mRNA. The sequences of cDNAs encoding human
IGF-I and IGF-II are presented.
IT 93052-02-9 93052-03-0
RL: PRP (Properties)
(amino acid sequence of)
RN 93052-02-9 HCAPLUS
CN Insulin-like growth factor II, prepro- (human reduced) (9CI) (CA INDEX
NAME)
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 93052-03-0 HCAPLUS
CN Insulin-like growth factor II, pro- (human reduced) (9CI) (CA INDEX NAME)
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L12 ANSWER 21 OF 25 HCPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1987:417932 HCPLUS
 DOCUMENT NUMBER: 107:17932
 TITLE: E-domain peptide of rat proinsulin-like growth factor-II: validation of a radioimmunoassay and measurement in culture medium and rat serum
 AUTHOR(S): Hylka, Vincent W.; Kent, Stephen B. H.; Straus, Daniel S.
 CORPORATE SOURCE: Div. Biomed. Sci., Univ. California, Riverside, CA, 92521-0121, USA
 SOURCE: Endocrinology (1987), 120(5), 2050-8
 CODEN: ENDOAO; ISSN: 0013-7227
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB A peptide has recently been discovered which is derived from the C-terminal portion of the E-domain of rat proinsulin-like growth factor II (pro-IGF-II) in medium conditioned by BRL-3A rat liver cells. This peptide begins at residue 117 in the pro-IGF-II sequence. To measure physiol. concns. of this peptide in serum, an RIA was established for a synthetic peptide [rat pro-IGF-II-(117-156); E-domain peptide] corresponding to the C-terminal 40-amino acids of rat pro-IGF-II. The 41-residue peptide [Tyr116]pro-IGF-II-(117-156) was also synthesized and iodinated for use as tracer. Using polyclonal antibodies, a standard curve was established that measured as little as 25 pg/tube. Tracer was not displaced by insulin, human (h) IGF-I, hIGF-II, pro-hIGF-I-(71-105), rat GH, mouse EGF, ACTH, bovine PTH, ovine FSH, TRH, or LH-RH under these assay conditions. However, a synthetic analog of the E-domain peptide [Phe117]pro-IGF-II-(118-156) showed displacement similar to that of the synthetic E-domain peptide. Serial dilns. of either culture medium or rat serum exhibited displacement parallel to the standard curve. Measurement of E-domain peptide in serum-free medium conditioned by BRL-3A rat liver cells showed a time-related increase in E-peptide concentration over a 72-h period. Anal. of E-peptide immunoreactivity from conditioned medium after gel filtration chromatog. in 1M acetic acid revealed a single peak which had a mol. weight (determined by Western blot) identical to that of the synthetic E-peptide standard. The concentration of immunoreactive E-domain peptide levels in serum of 5-day-old

rat pups was 30-40-fold higher than concns. in the serum of adult rats. Gel filtration chromatog. of adult rat serum in 1M acetic acid revealed a single major peak of immunoreactivity eluting at a position similar to the elution position of the E-domain peptide from BRL-3A rat liver cell-conditioned medium. The RIA described here should prove useful for measurement of the somatic output of E-domain peptide under different physiol. conditions.

IT 96162-27-5
 RL: ANT (Analyte); ANST (Analytical study)
 (determination of, by RIA)

RN 96162-27-5 HCPLUS

CN Insulin-like growth factor II, pro- (rat clone 30 reduced) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L12 ANSWER 22 OF 25 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1987:28290 HCAPLUS
 DOCUMENT NUMBER: 106:28290
 TITLE: cDNA encoding mammalian insulin-like growth factor II
 INVENTOR(S): Soares, Marcelo Bento; Efstratiadis, Argiris
 PATENT ASSIGNEE(S): Columbia University, USA
 SOURCE: Eur. Pat. Appl., 36 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 193112	A2	19860903	EP 1986-102206	19860220
EP 193112	A3	19870225		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
JP 61234785	A2	19861020	JP 1986-37143	19860221

PRIORITY APPLN. INFO.: US 1985-704625 A 19850222
 AB A heterogeneous population (≥ 3) of mRNA transcripts encoding rat insulinlike growth factor II (rIGF II) is isolated. These different mRNA transcripts appear to be tissue specific. The 1.6-kb and 1.75-kb rIGF II mRNA transcripts are found predominantly in brain and lung tissues, and the 3.4-kb transcript, in neonatal and muscle tissues. The mRNA transcripts can be used to make cDNA clones for the production of tissue-specific rIGF II polypeptides. A composite of the DNA sequence of prepro-rIGF II derived from 6 clones from a cDNA library [isolated by hybridization of poly(A) RNA of BRL-3A cells using a synthetic oligonucleotide probe corresponding to the first 13 amino acids of the A domain of rIGF-II] is presented.

IT 94046-85-2
 RL: PRP (Properties)
 (amino acid sequence of)
 RN 94046-85-2 HCAPLUS
 CN Insulin-like growth factor II, prepro- (rat clone 30 reduced) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L12 ANSWER 23 OF 25 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1986:620240 HCAPLUS
 DOCUMENT NUMBER: 105:220240
 TITLE: Preproinsulin-like growth factors I and II
 INVENTOR(S): Bell, Graeme I.; Rall, Leslie B.; Merryweather, James P.
 PATENT ASSIGNEE(S): Chiron Corp., USA
 SOURCE: PCT Int. Appl., 21 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 8600619	A1	19860130	WO 1985-US1325	19850710
W: JP				
RW: BE, CH, DE, FR, GB, IT, NL, SE				
EP 189481	A1	19860806	EP 1985-904699	19850710
EP 189481	B1	19910123		
R: BE, CH, DE, FR, GB, IT, LI, NL, SE				
JP 61502657	T2	19861120	JP 1985-504128	19850710
US 5405942	A	19950411	US 1987-65673	19870616
PRIORITY APPLN. INFO.:			US 1984-630557	A 19840713
			WO 1985-US1325	W 19850710

AB DNA sequences encoding human preproinsulin-like **growth** factors I and II are isolated by screening a cDNA library obtained from human liver cells using a hybridization probe encoding an 8-amino-acid sequence common to the sequences of insulinlike **growth** factors (IGF) I and II. The DNA sequences may be used for cloning and expression of mature IGF in suitable hosts, as well as for the production of hybridization probes.

IT 93052-02-9

RL: PRP (Properties)
 (amino acid sequence of)

RN 93052-02-9 HCAPLUS

CN Insulin-like growth factor II, prepro- (human reduced) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L12 ANSWER 24 OF 25 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1985:180060 HCAPLUS
DOCUMENT NUMBER: 102:180060
TITLE: Developmental and tissue-specific expression of a family of transcripts related to rat insulin-like growth factor II mRNA
AUTHOR(S): Soares, Marcelo Bento; Ishii, Douglas N.; Efstratiadis, Argiris
CORPORATE SOURCE: Dep. Hum. Genet., Columbia Univ., New York, NY, 10032, USA
SOURCE: Nucleic Acids Research (1985), 13(4), 1119-34
CODEN: NARHAD; ISSN: 0305-1048
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A cDNA library was constructed from the mRNA of a rat liver cell line (BRL-3A) and cDNA clones encoding the protein precursor of the rat insulin-like growth factor II (pre-pro-rIGF-II) [67763-97-7] were characterized. This precursor, inferred from the nucleotide sequence, consists of a signal peptide, the rIGF-II sequence, and a trailer polypeptide of unknown significance. The characterized cDNA sequence (1016 nucleotides) is part of a 3.4 kilobase (kb) mRNA species. Northern anal. reveals that a probe containing the extreme 5'-noncoding region hybridizes to a 2nd RNA (1.6 kb), whereas a probe corresponding to the 5'-noncoding region proximal to the coding region hybridizes to 2 other RNA species (1.75 and 1.1 kb). All 4 RNAs are differentially expressed in all of the neonatal tissues that were examined, whereas the 3.4-kb pre-pro-rIGF-II mRNA and the 1.1-kb transcript are absent from adult tissues.

IT 94046-85-2 96162-27-5

RL: PRP (Properties)
(amino acid sequence of)

RN 94046-85-2 HCAPLUS

CN Insulin-like growth factor II, prepro- (rat clone 30 reduced) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 96162-27-5 HCAPLUS

CN Insulin-like growth factor II, pro- (rat clone 30 reduced) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L12 ANSWER 25 OF 25 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1984:605168 HCAPLUS
DOCUMENT NUMBER: 101:205168
TITLE: Sequence of a cDNA clone encoding human
preproinsulin-like growth factor II
AUTHOR(S): Bell, Graeme I.; Merryweather, James P.;
Sanchez-Pescador, Ray; Stempien, Michelle M.;
Priestley, Linda; Scott, James; Rall, Leslie B.
CORPORATE SOURCE: Chiron Corp., Emeryville, CA, 94608, USA
SOURCE: Nature (London, United Kingdom) (1984), 310(5980),
775-7
DOCUMENT TYPE: CODEN: NATUAS; ISSN: 0028-0836
Journal
LANGUAGE: English
AB The insulin-like growth factors (IGF) I and II are single-chain
serum proteins of 70 and 67 amino acids, resp., which are synthesized by
the liver and possibly other tissues. They are probably required for
normal fetal and postnatal growth and development. They also
stimulate the growth of cultured cells. As a 1st step
in studying the biosynthesis of these proteins and elucidating their
role(s) in normal development and in tumorigenesis, cDNAs prepared from
adult human liver mRNA which encode the precursors to IGF-I and -II were
isolated and sequenced. The sequence of a cDNA encoding an 180-amino acid
protein which is the precursor to IGF-II is given.
IT 93052-02-9 93052-03-0
RL: PRP (Properties)
(amino acid sequence of)
RN 93052-02-9 HCAPLUS
CN Insulin-like growth factor II, prepro- (human reduced) (9CI) (CA INDEX
NAME)
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 93052-03-0 HCAPLUS
CN Insulin-like growth factor II, pro- (human reduced) (9CI) (CA INDEX NAME)
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

Kosar 10632366

```
=> => select hitrn 18 1-8
'HITRN' IS NOT A VALID FIELD CODE FOR FILE 'HCAPLUS'
ENTER DISPLAY CODE (TI) OR ?:end
```

```
=> select hit rn 18 1-8
E1 THROUGH E7 ASSIGNED
```

```
=> select hit rn 112 1-25
E8 THROUGH E28 ASSIGNED
```

```
=> fil reg
FILE 'REGISTRY' ENTERED AT 11:06:08 ON 20 MAY 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)
```

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 19 MAY 2006 HIGHEST RN 885029-44-7
DICTIONARY FILE UPDATES: 19 MAY 2006 HIGHEST RN 885029-44-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

```
*****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,      *
* effective March 20, 2005. A new display format, IDERL, is now        *
* available and contains the CA role and document type information.  *
*
*****
```

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

```
=>
=>
```

```
=> => d .seq 15 1-4
YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:n
```

```
=> => d ide can 12 1-6
```

Kosar 10632366

L2 ANSWER 1 OF 6 REGISTRY COPYRIGHT 2006 ACS on STN
RN 315197-75-2 REGISTRY
ED Entered STN: 19 Jan 2001
CN L-Leucine, L- α -aspartyl-L-valyl-L-seryl-L-threonyl-L-seryl-L-
glutaminyl-L-alanyl-L-valyl-L-leucyl-L-prolyl-L- α -aspartyl-L- α -
aspartyl-L-phenylalanyl-L-prolyl-L-arginyl-L-tyrosyl-L-prolyl-L-
valylglycyl-L-lysyl-L-phenylalanyl-L-phenylalanyl-L-glutaminyl-L-tyrosyl-L-
 α -aspartyl-L-threonyl-L-tryptophyl-L-arginyl-L-glutaminyl-L-seryl-L-
alanylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5: PN: WO0078805 PAGE: 27 claimed protein
CN Preptin (mouse)
FS PROTEIN SEQUENCE
MF C180 H264 N48 O53
CI MAN
SR CA
LC STN Files: BIOSIS, CA, CAPLUS, TOXCENTER, USPATFULL

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***

4 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:157935

REFERENCE 2: 140:157934

REFERENCE 3: 136:145438

REFERENCE 4: 134:66711

L2 ANSWER 2 OF 6 REGISTRY COPYRIGHT 2006 ACS on STN
RN 315197-73-0 REGISTRY
ED Entered STN: 19 Jan 2001
CN L-Leucine, L- α -aspartyl-L-valyl-L-seryl-L-threonyl-L-seryl-L-
glutaminyl-L-alanyl-L-valyl-L-leucyl-L-prolyl-L- α -aspartyl-L- α -
aspartyl-L-phenylalanyl-L-prolyl-L-arginyl-L-tyrosyl-L-prolyl-L-
valylglycyl-L-lysyl-L-phenylalanyl-L-phenylalanyl-L-lysyl-L-phenylalanyl-L-
 α -aspartyl-L-threonyl-L-tryptophyl-L-arginyl-L-glutaminyl-L-seryl-L-
alanylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 3: PN: WO0078805 PAGE: 27 claimed protein

CN **Preptin (rat)**

FS PROTEIN SEQUENCE

MF C181 H268 N48 O51

CI MAN

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***

3 REFERENCES IN FILE CA (1907 TO DATE)

3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:157935

REFERENCE 2: 140:157934

REFERENCE 3: 134:66711

L2 ANSWER 3 OF 6 REGISTRY COPYRIGHT 2006 ACS on STN

RN 315197-69-4 REGISTRY

ED Entered STN: 19 Jan 2001

CN L-Leucine, L- α -aspartyl-L-valyl-L-seryl-L-threonyl-L-prolyl-L-prolyl-L-threonyl-L-valyl-L-leucyl-L-prolyl-L- α -aspartyl-L-asparaginyl-L-phenylalanyl-L-prolyl-L-arginyl-L-tyrosyl-L-prolyl-L-valylglycyl-L-lysyl-L-phenylalanyl-L-phenylalanyl-L-glutaminyl-L-tyrosyl-L- α -aspartyl-L-threonyl-L-tryptophyl-L-lysyl-L-glutaminyl-L-seryl-L-threonyl-L-glutaminyl-L-arginyl- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 1: PN: WO0078805 PAGE: 27 claimed protein

CN Preptin (human)

FS PROTEIN SEQUENCE

MF C187 H275 N47 O53

CI MAN

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***

3 REFERENCES IN FILE CA (1907 TO DATE)

3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:157935

REFERENCE 2: 140:157934

REFERENCE 3: 134:66711

Kosar 10632366

L2 ANSWER 4 OF 6 REGISTRY COPYRIGHT 2006 ACS on STN
RN 314780-99-9 REGISTRY
ED Entered STN: 18 Jan 2001
CN DNA (mouse preptin gene) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 6: PN: WO0078805 PAGE: 30 claimed DNA
FS NUCLEIC ACID SEQUENCE
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:66711

Kosar 10632366

L2 ANSWER 5 OF 6 REGISTRY COPYRIGHT 2006 ACS on STN
RN 314780-98-8 REGISTRY
ED Entered STN: 18 Jan 2001
CN DNA (rat preptin gene) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 4: PN: WO0078805 PAGE: 30 claimed DNA
FS NUCLEIC ACID SEQUENCE
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:66711

Kosar 10632366

L2 ANSWER 6 OF 6 REGISTRY COPYRIGHT 2006 ACS on STN
RN 314780-97-7 REGISTRY
ED Entered STN: 18 Jan 2001
CN DNA (human preptin gene) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 2: PN: WO0078805 PAGE: 30 claimed DNA
FS NUCLEIC ACID SEQUENCE
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:66711

Kosar 10632366

=> => d stat que l14
L1 76 SEA FILE=REGISTRY ABB=ON PLU=ON DVSTPPPTVLPDNFPRYPVGKFFQYDTWKQ
STQRL|DVSTSQAVLPDDFPRYPVGKFFKFDTWRQSAGRL|DVSTSQAVLPDDFPRYPVGKFF
QYDTWRQSAGRL/SQSP
L13 28 SEA FILE=REGISTRY ABB=ON PLU=ON (481287-00-7/BI OR 309257-18-
9/BI OR 537723-29-8/BI OR 628822-82-2/BI OR 680884-69-9/BI OR
742221-41-6/BI OR 853830-43-0/BI OR 93052-02-9/BI OR 94046-85-2
/BI OR 96162-27-5/BI OR 93052-03-0/BI OR 253578-19-7/BI OR
253578-20-0/BI OR 340836-88-6/BI OR 454747-09-2/BI OR 481286-95
-7/BI OR 500742-70-1/BI OR 516534-81-9/BI OR 632394-04-8/BI OR
643773-30-2/BI OR 671823-44-2/BI OR 746279-18-5/BI OR 746327-21
-9/BI OR 746327-26-4/BI OR 864396-45-2/BI OR 869138-89-6/BI OR
871755-52-1/BI OR 93927-44-7/BI)
L14 28 SEA FILE=REGISTRY ABB=ON PLU=ON L13 AND L1

=> d .seq l14 1-28

Kosar 10632366

L14 ANSWER 1 OF 28 REGISTRY COPYRIGHT 2006 ACS on STN
RN 871755-52-1 REGISTRY
CN 2: PN: US20050281805 SEQID: 2 unclaimed protein (9CI) (CA INDEX NAME)
SQL 180
RN 871755-52-1 REGISTRY

SEQ 51 YFSRPASRVS RRSRGIVEEC CFRSCDLALL ETYCATPAKS ERDVSTPPTV
===== 101 LPDNFPRYPV GKFFQYDTWK QSTQRLRGL PALLRARRGH VLAKELEAFR
===== ===== =====
HITS AT: 93-126

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 144:64367

Kosar 10632366

L14 ANSWER 2 OF 28 REGISTRY COPYRIGHT 2006 ACS on STN
RN 869138-89-6 REGISTRY
CN Preeclampsia-associated protein (human clone US20050255114-SEQID-971)
(9CI) (CA INDEX NAME)

OTHER NAMES:

CN 971: PN: US20050255114 SEQID: 971 claimed protein

SQL 275

RN 869138-89-6 REGISTRY

SEQ 151 ASRVSRRSRG IVEECCFRSC DLALLETYCA TPAKSERDVS TPPTVLPDNF
===== =====
201 PRYPVGKFFQ YDTWKQSTQR LRRGLPALLR ARRGHVLAKE LEAFREAKRH
===== ===== =

HITS AT: 188-221

REFERENCE 1: 143:457991

Kosar 10632366

L14 ANSWER 3 OF 28 REGISTRY COPYRIGHT 2006 ACS on STN
RN 864396-45-2 REGISTRY
CN 14: PN: US20050202479 SEQID: 25 unclaimed protein (9CI) (CA INDEX NAME)
SQL 180
RN 864396-45-2 REGISTRY

SEQ 51 YFSRPASRVS RRSRGIVEEC CFRSCDLALL ETYCATPAKS ERDVSTPPTV
=====
101 LPDNFPRYPV GKFFQYDTWK QSTQRLRRGL PALLRARRGH VLAKELAEFR
===== ===== =====

HITS AT: 93-126

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 143:300322

Kosar 10632366

L14 ANSWER 4 OF 28 REGISTRY COPYRIGHT 2006 ACS on STN
RN 853830-43-0 REGISTRY
CN 38: PN: US20050130926 SEQID: 38 unclaimed protein (9CI) (CA INDEX NAME)
SQL 180
RN 853830-43-0 REGISTRY

SEQ 51 YFSRPASRVS RRSRGIVEEC CFRSCDLALL ETYCATPAKS ERDVSTPPTV
=====
101 LPDNFPRYPV GKFFQYDTWK QSTQRLRRGL PALLRARRGH VLAKELEAFR
===== ===== =====

HITS AT: 93-126

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 143:58021

Kosar 10632366

L14 ANSWER 5 OF 28 REGISTRY COPYRIGHT 2006 ACS on STN
RN 746327-26-4 REGISTRY
CN Tumor-associated protein (human clone hP15-022.2) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 342: PN: WO2004074320 SEQID: 344 claimed protein
SQL 180
RN 746327-26-4 REGISTRY

SEQ 51 YFSRPASRVS RRSRGIVEEC CFRSCDLALL ETYCATPAKS ERDVSTPPTV
=====

101 LPDNFPRYPV GKFFQYDTWK QSTQRLRRGL PALLRARRGH VLAKELEAFR
===== ===== =====

HITS AT: 93-126

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 141:218948

Kosar 10632366

L14 ANSWER 6 OF 28 REGISTRY COPYRIGHT 2006 ACS on STN
RN 746327-21-9 REGISTRY
CN Tumor-associated protein (Mus clone mP15-022.1) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 337: PN: WO2004074320 SEQID: 339 claimed protein
SQL 353
RN 746327-21-9 REGISTRY

SEQ 251 ALLETYCATP AKSERDVSTS QAVLPDDFPR YPVGKFFQYD TWRQSAGRLR
===== ===== ===== ===== =====

HITS AT: 266-299

REFERENCE 1: 141:218948

Kosar 10632366

L14 ANSWER 7 OF 28 REGISTRY COPYRIGHT 2006 ACS on STN
RN 746279-18-5 REGISTRY
CN Protein (human clone BRACE3026345) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 65: PN: EP1447413 SEQID: 2082 claimed protein
SQL 180
RN 746279-18-5 REGISTRY

SEQ 51 YFSRPASRVS RRSRGIVEEC CFRSCDLALL ETYCATPAKS ERDVSTPPTV
=====

101 LPDNFPRYPV GKFFQYDTWK QSTQRLRRGL PALLRARRGH VLAKLEAFR
===== ===== =====

HITS AT: 93-126

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 141:219974

Kosar 10632366

L14 ANSWER 8 OF 28 REGISTRY COPYRIGHT 2006 ACS on STN
RN 742221-41-6 REGISTRY
CN 46: PN: WO2004070012 SEQID: 46 unclaimed protein (9CI) (CA INDEX NAME)
SQL 180
RN 742221-41-6 REGISTRY

SEQ 51 YFSRPASRVS RRSRGIVEEC CFRSCDLALL ETYCATPAKS ERDVSTPPTV
=====
101 LPDNFPRYPV GKFFQYDTWK QSTQRLRRGL PALLRARRGH VLAKELAEFR
===== ===== =====
HITS AT: 93-126

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 141:200162

Kosar 10632366

L14 ANSWER 9 OF 28 REGISTRY COPYRIGHT 2006 ACS on STN
RN **680884-69-9** REGISTRY
CN Tumor-associated antigen PRO124 (human) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 121: PN: WO2004030615 SEQID: 3121 claimed protein
SQL 180
RN **680884-69-9** REGISTRY

SEQ 51 YFSRPASRVS RRSRGIVEEC CFRSCDLALL ETYCATAKS ERDVSTPPTV
=====

101 LPDNFPRYPV GKFFQYDTWK QSTQRLRGL PALLRARRGH VLAKELAEFR
===== ===== =====

HITS AT: 93-126

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 140:351720

Kosar 10632366

L14 ANSWER 10 OF 28 REGISTRY COPYRIGHT 2006 ACS on STN
RN 671823-44-2 REGISTRY
CN 19: PN: US6709659 SEQID: 19 unclaimed protein (9CI) (CA INDEX NAME)
SQL 180
RN 671823-44-2 REGISTRY

SEQ 51 YFSRPASRVS RRSRGIVEEC CFRSCDLALL ETYCATPAKS ERDVSTPPPTV
===== 101 LPDNFPRYPV GKFFQYDTWK QSTQRLRRGL PALLRARRGH VLAKELAEFR
===== ===== =====

HITS AT: 93-126

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 140:269540

Kosar 10632366

L14 ANSWER 11 OF 28 REGISTRY COPYRIGHT 2006 ACS on STN
RN 643773-30-2 REGISTRY
CN 2: PN: US20040006008 SEQID: 2 unclaimed protein (9CI) (CA INDEX NAME)
SQL 180
RN 643773-30-2 REGISTRY

SEQ 51 YFSRPASRVS RRSRGIVEEC CFRSCDLALL ETYCATPAKS ERDVSTPPTV
=====

101 LPDNFPRYPV GKFFQYDTWK QSTQRLRRL PALLRARRGH VLAKELAEFR
===== ===== =====

HITS AT: 93-126

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 140:99586

Kosar 10632366

L14 ANSWER 12 OF 28 REGISTRY COPYRIGHT 2006 ACS on STN
RN 632394-04-8 REGISTRY
CN 2: PN: WO03102583 SEQID: 2 unclaimed protein (9CI) (CA INDEX NAME)
SQL 180
RN 632394-04-8 REGISTRY

SEQ 51 YFSRPASRVS RRSRGIVEEC CFRSCDLALL ETYCATPAKS ERDVSTPPTV
=====

101 LPDNFPRYPV GKFFQYDTWK QSTQRLRRGL PALLRARRGH VLAKELEAFR
===== ===== =====

HITS AT: 93-126

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 140:23197

Kosar 10632366

L14 ANSWER 13 OF 28 REGISTRY COPYRIGHT 2006 ACS on STN
RN 628822-82-2 REGISTRY
CN 13: PN: WO03100008 SEQID: 21 unclaimed protein (9CI) (CA INDEX NAME)
SQL 180
RN 628822-82-2 REGISTRY

SEQ 51 YFSRPASRVS RRSRGIVEEC CFRSCDLALL ETYCATPAKS ERDVSTPPTV
=====
101 LPDNFPRYPV GKFFQYDTWK QSTQRLRGL PALLRARRGH VLAKELAEFR
===== ===== =====
HITS AT: 93-126

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 140:26911

Kosar 10632366

L14 ANSWER 14 OF 28 REGISTRY COPYRIGHT 2006 ACS on STN
RN 537723-29-8 REGISTRY
CN Tumor-associated protein (human clone WO03042661-SEQID-199) (9CI) (CA
INDEX NAME)

OTHER NAMES:

CN 511: PN: WO03042661 TABLE: 78 claimed sequence

SQL 180

RN 537723-29-8 REGISTRY

SEQ 51 YFSRPASRVS RRSRGIVEEC CFRSCDLALL ETYCATPAKS ERDVSTPPPTV
=====

101 LPDNFPRYPV GKFFQYDTWK QSTQRLRGL PALLRARRGH VLAKLEAFR
===== ===== =====

HITS AT: 93-126

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 139:18315

Kosar 10632366

L14 ANSWER 15 OF 28 REGISTRY COPYRIGHT 2006 ACS on STN
RN 516534-81-9 REGISTRY
CN Somatomedin A (human clone OV58 gene IGF2) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 145: PN: US20030087250 SEQID: 145 claimed protein
SQL 180
RN 516534-81-9 REGISTRY

SEQ 51 YFSRPASRVS RRSRGIVEEC CFRSCDLALL ETYCATAKS ERDVSTPPTV
=====

101 LPDNFPRYPV GKFFQYDTWK QSTQRLRRGL PALLRARRGH VLAKLEAFR
===== ===== =====

HITS AT: 93-126

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 138:335902

Kosar 10632366

L14 ANSWER 16 OF 28 REGISTRY COPYRIGHT 2006 ACS on STN
RN 500742-70-1 REGISTRY
CN 36: PN: US20030045491 SEQID: 38 unclaimed protein (9CI) (CA INDEX NAME)
SQL 180
RN 500742-70-1 REGISTRY

SEQ 51 YFSRPASRVS RRSRGIVEEC CFRSCDLALL ETYCATPAKS ERDVSTPPPTV
=====

101 LPDNFPRYPV GKFFQYDTWK QSTQRLRRGL PALLRARRGH VLAKELEAFR
===== ===== =====

HITS AT: 93-126

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 138:217879

Kosar 10632366

L14 ANSWER 17 OF 28 REGISTRY COPYRIGHT 2006 ACS on STN
RN 481287-00-7 REGISTRY
CN Protein (human gene IGF2) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 3391: PN: WO03091391 TABLE: 20 unclaimed protein
CN 4691: PN: WO03091391 FIGURE: 21 unclaimed protein
CN 573: PN: WO03091391 FIGURE: 18 unclaimed protein
CN 951: PN: WO2004038376 TABLE: 5 unclaimed protein
CN GenBank AAA52545
CN GenBank AAA52545 (Translated from: GenBank J03242)
SQL 180
RN 481287-00-7 REGISTRY

SEQ 51 YFSRPASRVS RRSRGIVEEC CFRSCDLALL ETYCATPAKS ERDVSTPPTV
=====

101 LPDNFPRYPV GKFFQYDTWK QSTQRLRRL PALLRARRGH VLAKELEAFR
===== ===== =====

HITS AT: 93-126

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 140:402911
REFERENCE 2: 140:248186
REFERENCE 3: 140:40262
REFERENCE 4: 140:3792
REFERENCE 5: 139:363045

Kosar 10632366

L14 ANSWER 18 OF 28 REGISTRY COPYRIGHT 2006 ACS on STN
RN 481286-95-7 REGISTRY
CN Insulin-like growth factor (human gene IGF2) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN GenBank AAA52535
CN GenBank AAA52535 (Translated from: GenBank M14118)
SQL 180
RN 481286-95-7 REGISTRY

SEQ 51 YFSRPASRVS RRSRGIVEEC CFRSCDLALL ETYCATPAKS ERDVSTPPTV
=====

101 LPDNFPRYPV GKFFQYDTWK QSTQRLRRGL PALLRARRGH VLAKELEAFR
===== ===== =====

HITS AT: 93-126

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 140:126701

Kosar 10632366

L14 ANSWER 19 OF 28 REGISTRY COPYRIGHT 2006 ACS on STN
RN 454747-09-2 REGISTRY
CN 38: PN: WO02068444 SEQID: 38 unclaimed protein (9CI) (CA INDEX NAME)
SQL 180
RN 454747-09-2 REGISTRY

SEQ 51 YFSRPASRVS RRSRGIVEEC CFRSCDLALL ETYCATPAKS ERDVSTPPTV
=====

101 LPDNFPRYPV GKFFQYDTWK QSTQRLRRGL PALLRARRGH VLAKELEAFR
===== ===== =====

HITS AT: 93-126

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 137:215235

Kosar 10632366

L14 ANSWER 20 OF 28 REGISTRY COPYRIGHT 2006 ACS on STN
RN 340836-88-6 REGISTRY
CN 14: PN: US6235874 FIGURE: 2B unclaimed protein (9CI) (CA INDEX NAME)
SQL 89
RN 340836-88-6 REGISTRY

SEQ 1 RDVSTSQAVL PDDFPRYPVG KFFQYDTWRQ SAGRLRRGLP ALLRARRGRM
===== ===== ===== =====

HITS AT: 2-35

REFERENCE 1: 135:1955

Kosar 10632366

L14 ANSWER 21 OF 28 REGISTRY COPYRIGHT 2006 ACS on STN
RN 309257-18-9 REGISTRY
CN 202: PN: WO0069900 SEQID: 381 unclaimed protein (9CI) (CA INDEX NAME)
SQL 35
RN 309257-18-9 REGISTRY

SEQ 1 RDVSTPPPTVL PDNFPRYPVG KFFQYDTWKQ STQRL
===== ===== ===== =====

HITS AT: 2-35

REFERENCE 1: 134:21425

Kosar 10632366

L14 ANSWER 22 OF 28 REGISTRY COPYRIGHT 2006 ACS on STN
RN 253578-20-0 REGISTRY
CN 15: PN: US6010882 FIGURE: 2 unclaimed protein (9CI) (CA INDEX NAME)
SQL 113
RN 253578-20-0 REGISTRY

SEQ 1 MGIPVGKSML VLLISLAFAL CCIARDVSTS QAVLPDDFPR YPVGKFFQYD
===== ===== =====
51 TWRQSAGRLR RGLPALLRAR RGRMLAKELK EFREAKRHRP LIVLPPKDPA
=====

HITS AT: 26-59

REFERENCE 1: 132:74537

Kosar 10632366

L14 ANSWER 23 OF 28 REGISTRY COPYRIGHT 2006 ACS on STN
RN 253578-19-7 REGISTRY
CN 14: PN: US6010882 FIGURE: 2 unclaimed protein (9CI) (CA INDEX NAME)
SQL 113
RN 253578-19-7 REGISTRY

SEQ 1 MGIPVGKSML VLLISLAFAL CCIARDVSTS QAVLPDDFPR YPVGKFFKFD
===== ===== =====
51 TWRQSAGRRLR RGLPALLRAR RGRMLAKELE AFREAKRHRP LIVLPPKDPA
=====

HITS AT: 26-59

REFERENCE 1: 132:74537

Kosar 10632366

L14 ANSWER 24 OF 28 REGISTRY COPYRIGHT 2006 ACS on STN
RN 96162-27-5 REGISTRY
CN Insulin-like growth factor II, pro- (rat clone 30 reduced) (9CI) (CA
INDEX NAME)

OTHER NAMES:

CN Insulin-like growth factor II, pro- (rat reduced)

SQL 156

RN 96162-27-5 REGISTRY

SEQ 51 CDLALLETYC ATPAKSERDV STSQAVLPDD FPRYPVGKFF KFDTWRQSAG
101 RLRRGLPALL RARRGRMLAK ELEAFREAKR HRPLIVLPPK DPAHGGASSE
==

HITS AT: 69-102

REFERENCE 1: 117:84401

REFERENCE 2: 107:17932

REFERENCE 3: 102:180060

REFERENCE 4: 102:18643

Kosar 10632366

L14 ANSWER 25 OF 28 REGISTRY COPYRIGHT 2006 ACS on STN
RN 94046-85-2 REGISTRY
CN Insulin-like growth factor II, prepro- (rat clone 30 reduced) (9CI) (CA
INDEX NAME)

OTHER NAMES:

CN 2: PN: WO0183705 SEQID: 2 unclaimed protein
SQL 180
RN 94046-85-2 REGISTRY

SEQ 51 YFSRPSSRAN RRSRGIVEEC CFRSCDLALL ETYCATPAKS ERDVSTSQAV
=====

101 LPDDFPRYPV GKFFKFDTWR QSAGRLRRGL PALLRARRGR MLAKELEAFR
===== ===== =====

HITS AT: 93-126

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 135:353853

REFERENCE 2: 117:84401

REFERENCE 3: 109:223680

REFERENCE 4: 106:28290

REFERENCE 5: 105:220119

REFERENCE 6: 102:180060

REFERENCE 7: 102:18643

Kosar 10632366

L14 ANSWER 26 OF 28 REGISTRY COPYRIGHT 2006 ACS on STN
RN 93927-44-7 REGISTRY
CN Insulin-like growth factor II (rat E-peptide) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 13: PN: US6235874 FIGURE: 2B unclaimed protein
SQL 89
RN 93927-44-7 REGISTRY

SEQ 1 RDVSTSQAVL PDDFPRYPVG KFFKFDTWRQ SAGRLRRGLP ALLRARRGRM
===== ===== ===== =====

HITS AT: 2-35

REFERENCE 1: 135:1955

REFERENCE 2: 102:18643

Kosar 10632366

L14 ANSWER 27 OF 28 REGISTRY COPYRIGHT 2006 ACS on STN
RN 93052-03-0 REGISTRY
CN Insulin-like growth factor II, pro- (human reduced) (9CI) (CA INDEX NAME)
SQL 156
RN 93052-03-0 REGISTRY

SEQ 51 CDLALLETYC ATPAKSERDV STPPTVLPDN FPRYPVGKFF QYDTWKQSTQ
101 RLRRGLPALL RARRGHVLAK ELEAFREAKR HRPLIALPTQ DPAHGGAPPE
==
HITS AT: 69-102

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 108:125844
REFERENCE 2: 107:212805
REFERENCE 3: 104:143007
REFERENCE 4: 102:198845
REFERENCE 5: 102:18643
REFERENCE 6: 101:205168

Kosar 10632366

L14 ANSWER 28 OF 28 REGISTRY COPYRIGHT 2006 ACS on STN
RN 93052-02-9 REGISTRY
CN Insulin-like growth factor II, prepro- (human reduced) (9CI) (CA INDEX
NAME)
SQL 180
RN 93052-02-9 REGISTRY

SEQ 51 YFSRPASRVS RRSRGIVEEC CFRSCDLALL ETYCATPAKS ERDVSTPPTV
=====
101 LPDNFPRYPV GKFFQYDTWK QSTQRLRRGL PALLRARRGH VLAKELEAFR
===== ===== =====

HITS AT: 93-126

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 132:219214
REFERENCE 2: 110:206856
REFERENCE 3: 109:32986
REFERENCE 4: 108:125844
REFERENCE 5: 107:212805
REFERENCE 6: 107:192128
REFERENCE 7: 105:220240
REFERENCE 8: 104:143007
REFERENCE 9: 102:198845
REFERENCE 10: 102:18643

Kosar 10632366

=>